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Abstract

Bovine Leukemia Virus (BLV) is an exogenous type-C
retrovirus which can induce an aleukemic (AL) stage, a
persistent lymphocytotic (PL) stage, or a lymphosarcomatous
(LS) stage in infected animals.

After experimental

infection with BLV, whole blood and serum samples were
obtained from 12 holstein heifers for 103 weeks and used to
correlate clinical signs (visual observation and white blood
cell counts) with changes in humoral immune response (Agar
gel immunodiffusion using envelope gp50 as primary antigen,
and ELISA and Western immunoblots using whole BLV as anti
gen) .

Monoclonal antibodies against BLV envelope gp50 and

gag p24 were produced to confirm reactivity to specific
proteins for the various assays.

To confirm reactivity of

monoclonals and produce large amounts of selected proteins
for later studies of BLV, the genes for env, gag, and pX
were cloned into eucaryotic expression vectors.

After

transfection of appropriate plasmids, correct expression of
cloned genes was confirmed using monoclonals and indirect
immunofluorescence for gp50 and p24 and CAT assay for px.
Total lymphocyte counts indicated 6 cattle reached the PL
stage during the 103 weeks post infection (PI).

Cows

progressed through three transient disease stages in the
first 3 months PI: transient eosinophilia, lymph node

x

enlargement and lymphocytosis.

Of the 6 cattle

demonstrating early transient lymph node enlargement, 5/6
were AL.

Changes in the humoral immune response to BLV were

best detected using Western immunoassays.

AL cattle were

more likely to have an increased antibody response to the
gag protein p24 early PI as compared to PL cattle.

PL

animals usually reached their highest p24 antibody responses
after conversion to the PL stage.

Antibody response to env

gp50 increased as a function of time PI regardless of
disease stage.

PL cattle tended to recognize a greater

number of the lesser gag proteins, pl5, pl2 and plO in the
first year PI than AL cattle.

All cattle decreased markedly

in their reactivity to any of these lesser proteins after 51
weeks PI.

Chapter I
REVIEW OF LITERATURE
Introduction

The most common neoplasm in cattle is lymphoid leukosis.
Bovine leukosis exists in two forms based on pathology and
seroepidemiology:

Sporadic Bovine Leukosis (SBL) and En

zootic Bovine Leukosis (EBL).

SBL is generally seen in

young animals (4 months to three years old), occurs as a
solitary case in a herd and is noncontagious with no known
viral etiology.

Non-B-cell lineage lymphoid tumors which

are multicentric, cutaneous, or thymic are seen, usually
with acute onset (Ghysdael et al., 1984; Olson 1974).

EBL

is a highly contagious disease induced by an exogenous type
C retrovirus, bovine leukemia virus (BLV) (Deschamps et al.,
1981).

It is a chronic disease, with tumors developing in

only a small number of infected animals over a period of
years.

BLV is related to human T lymphotrophic viruses

(HTLV-I and HTLV-II) with all three viruses having sequence
homologies (Burny et al., 1987b; Rice et al., 1987b).

They

possess a unique 3 1 open reading frame encoding a number of
viral regulatory proteins, hypothesized to influence the
progressive stages of malignancy.

Pathologically, there is

an absence of chronic viremia, long latent periods, and no
preferred site of proviral integration (Burny et al.,
1987b).

Because of these common features, it is proposed
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that BLV and HTLV be grouped into a new family of retro
viruses distinct from the nonacute and the acute (oncogenecontaining) transforming retroviruses (Rosen et al., 1985).
This review concerns the development of EBL.
Disease
Clinical Signs
Bovine leukemia virus induces three clinical manifesta
tions in infected cattle.

The first is an aleukemic (AL)

stage in which the BLV infected cow produces a serological
response to various BLV proteins, but is otherwise clinical
ly normal.

Persistent lymphocytosis (PL), the second stage,

occurs in 30-70% of BLV infected cattle and is characterized
by a benign non-malignant increase in the number of periph
eral blood lymphocytes (PBL).

The PL stage is characterized

by an increase in the absolute lymphocyte count of 2.5 or
more standard deviations above the normal mean as determined
for that respective breed and age group of animals in two
successive blood tests (Kenyon and Piper 1977a).

In five

year old Jersey cattle, this would be a lymphocyte count
greater than 7.5 x 103/ul of blood.

This increase in

circulating lymphocytes, primarily of B-cell lineage, can be
stabilized for long periods of time, increase, or suddenly
disappear, with a return to a normal white cell count (Ken
yon and Piper 1977a? Mikalauskiene et al., 1984; Burny et
al., 1987b).

Finally, a lymphosarcomatous (LS) or tumor

stage may result primarily in older animals (Marshak et al.,

1967).

PL precedes approximately two-thirds of the cases of

LS (Abt et al., 1969), in which immature lymphoid cells
circulate, the bone marrow may be invaded, and many organs
are invaded with cells of lymphoid lineage.

Tumors may

invade mammary glands, subcutaneous tissues, abdominal
muscles, diaphragm, heart, respiratory tract, and spinal
cord (Burny et al., 1980; Ferrer et al., 1980).

As tumors

grow, they mechanically impair normal function and generally
result in a chronically debilitated animal.

Enlarged lymph

or hemolymph nodes may or may not be seen externally, but a
majority of the cases will have enlarged pelvic lymph nodes
evident on rectal palpation (Burny et al., 1980; LaBelle and
Conner 1964).
Infection by BLV is a prerequisite for the production of
PL or LS stages; however, all infected animals do not
routinely exhibit these signs.

Many animals are clinically

normal and have lived for greater than 8 years (Olson 1974).
A large number of studies demonstrated familial aggregations
of PL and LS cases (Abt et al., 1969, 1976; Ferrer et al.,
1974; Burny et al., 1980; Stear et al., 1987).

Abt et al.

(1969, 1976) also found evidence that PL and LS stages may
aggregate along different family lines.

In 1976, Abt et al.

conducted a reciprocal foster nursing experiment involving
114 animals.

At the conclusion of the study, of the 80-92%

BLV positive calves obtained, PL was produced in 88% of PL
families, 21% of AL families and no PL was produced in

calves from the leukosis-free herds even though 90% became
infected with BLV.

Recent observations in a Shorthorn herd

suggested that the bovine lymphocyte antigen (BoLa) system
(inherited in Mendelian fashion) influenced susceptibility
of resistance to the PL or LS stages (Burny et al., 1987b).
A similar study of dairy cattle in Australia also indicated
a correlation between BoLa type and disease incidence (Stear
et al., 1988).

Although a strong familial influence in the

development of EBL occurs, the percentage of LS positive
cows increases with age, therefore, factors such as virus
dose, route of infection, age of infection, intercurrent
disease, or immunologic competence of the host must also be
considered (Burny et al., 1980, 1985a).
Economic Impact
Available U.S. data indicates a loss of approximately $44
million due to BLV and EBL.

This includes $1.6 million for

milk production, $40.5 million for replacement of LS cattle,
$0.5 million for veterinary care and $1.7 million for reduc
ed foreign trade from semen and embryos (Thurmond et al.,
1987) .
Milk production is not necessarily adversely affected by
BLV infection.

Although LS cows have a substantial drop in

milk production, many sero-positive cows tend to produce
more milk than non-infected cows in early lactations (Thur
mond 1987; Wu et al., 1989).

However, Thurmond (1987) found

longer non-lactating periods and a tendency to produce less

milk in antibody positive cows completing their second
lactations.

Wu et al., (1989), observed sero-positive cows,

both AL and PL, had a significantly greater genetic poten
tial and produced more milk than sero-negative animals.

The

genetic potential for fat production was also significantly
greater for PL cows than for AL or sero-negative cows.
However, the actual adjusted 305 day fat production was not
significantly different between groups indicating that PL
cows did not produce milk fat up to their genetic potential.
A premium is paid for increased fat levels in milk, there
fore, this decrease could deleteriously affect the total
income from milk production.
No significant differences for ages at first calving,
length of most recent calving interval, mean length of
calving interval, number of days open, number of times bred
or incidence of mastitis have been found between BLV sero
positive versus sero-negative animals (Huber et al., 1981;
Thurmond et al., 1987).

However, Thurmond et al., (1987)

did find a higher culling rate from a herd for BLV positive
cows.

Salvage value of these culled cows (to be used toward

a replacement animal) is greatly reduced over that of a
healthy cull.
Transmission

Transmission of BLV has been studied for over 100 years,
even before the etiologic agent was known.

Early observa

tions indicated EBL spread by addition of a sick animal to a

herd.

Horizontal spread is most common, including trans

placental transmission, and infected cells are the best
potential vehicles of spreading BLV (Burny et al., 1980,
1987b).
A marked increase of BLV prevalence in a herd occurs
between 1 & 2 years of age, and the percent of positive
cattle increases steadily with age (Miller and Van der
Maaten 1980; Burny et al., 1980, Romero et al., 1981; Hugh
Jones et al., 1984).

Most infections occur after calves are

introduced into the adult herd (Miller and Van der Maaten
1980).

Although rare, calves can be infected in utero as

evidenced by clinical observation or analysis of precolostral sera (Piper et al., 1979; Kono et al., 1983; Straub
1987b).

Van der Maaten et al. (1981), found initiation of

BLV infection during the first, second or third trimester of
pregnancy had no effect on the number of calves born with
BLV.

Calves can be exposed from infected dams via colostrum

or milk, especially when these products are contaminated by
blood (Miller and Van der Maaten 1979; Burny et al., 1980;
Ghysdael et al., 1984).

However, calves from sero-positive

dams are usually protected against milk-borne or contact
infection by passively acquired maternal antibodies (Piper
er al., 1979; Miller and Van der Maaten, 1980).

Colostral

antibodies have a half life of 20 days becoming undetectable
in most calves by 6 months (Kono et al., 1983; Straub
1987b).

Calves sero-negative at birth are more easily

infected and develop anti-BLV antibodies earlier than calves
that acquired and then subsequently lost their maternal
antibodies (Romero et al., 1981).

Of importance to man, BLV

is destroyed by commercial pasteurization (Olson 1974).
There is no evidence to suggest that other excretions or
secretions of BLV positive cattle could spread BLV.

These

include nasal secretions, saliva, urine and oviductal or
uterine flush fluids (Miller and Van der Maaten, 1979;
Ruckerbauer et al., 1988).

Zona pellucida-intact bovine

embryos can be transferred from BLV infected donors, includ
ing those bred by BLV-infected bulls (Baumgartener et al.,
1978), without risk of transmitting BLV, provided the
embryos are properly washed before transfer (Burny et al.,
1980, 1987b).

However, semen contaminated with infected

lymphocytes could spread BLV to cattle via contamination of
the cervical or uterine canal (Hopkins et al., 1988; Straub
1987b).

Roberts et al. (1982) demonstrated BLV transmission

by the intratracheal, subcutaneous, intradermal, or
intrauterine routes of infection using 5 x 106 infected
lymphocytes.

BLV could be detected in circulating PBL two

weeks post infection and two weeks before the appearance of
detectable serum antibodies, but virus was not found at any
time in the cell free plasma (Roberts et al., 1985).
The concentration of BLV infected cells in transmitted
fluids has a great effect on the ability to spread BLV.

PL

cows are much more likely to spread BLV among herd contacts

than are AL animals.

Studies have demonstrated almost 300

times more lymphocytes are needed from an AL cow than a PL
cow to transmit BLV, with blood volumes ranging from as
little as 5 ul in a PL cow to 500 ul in an AL animal.

(Van

der Maaten et al., 1981; Roberts et al., 1986; Burny et al.,
1987a).

This small amount of infectious fluids tends to in

criminate biting insects as possible mechanical vectors of
BLV.

This was inferred by Bech-Nielson et al. (1978) who

demonstrated contact transmission between BLV positive and
negative cattle was most prevalent during the summer months,
and BLV infected lymphocytes could be recovered from tabanids allowed to feed on BLV positive cows.

Foil et al.

(1988, 1989) demonstrated BLV transmission from a PL donor
cow to sheep, goats and calves with groups of 20 and 50
horse flies.
Routine veterinary care, such as vaccinating, tattooing
and dehorning, is another means of horizontal spread via
small amounts of contaminated blood (Burny et al., 1987b;
Hopkins et al., 1988).

Hopkins et al. (1988), demonstrated

colorectal transmission of BLV by gynecological examina
tions .
In addition to cattle, cases of natural BLV infection
have been found in sheep, capybara and water buffalo (Burny
et al., 1987b).

One of the first "outbreaks" of Enzootic

Leukosis in sheep was observed in a flock that had been pre
viously vaccinated for piroplasmosis using bovine blood

(Miller and Van der Maaten, 1980).

Rhode et al. (1978),

showed virus obtained from both BLV and ovine leukemia virus
samples, when run on SDS-polyacrylamide gels, were identi
cal.

The ability of BLV to induce leukosis in sheep has

been confirmed many times using whole blood, tumor cell
suspensions, cultured lymphocytes or supernatant fluids from
cultured lymphocytes as inoculum (Van der Maaten and Miller,
1975b; Kenyon et al., 1981; Rogers et al., 1984; Suneya et
al., 1984).

The most striking difference between ovine and

bovine leukosis is the increased susceptibility of sheep to
tumor induction and the rapidity with which it occurs as
compared to cattle (Miller and Van der Maaten, 1980; Burny
et al., 1980; Dimmock et al., 1986).

From 44% to 100% of

BLV infected sheep die of LS in a time period ranging from
15 months to 6.5 years post inoculation (Van der Maaten and
Miller 1975b; Miller and Van der Maaten 1980; Kenyon et al.,
1981; Ghysdael et al., 1984; Dimmock et al., 1986; Djilali
et al., 1987b;).

Remarkably, contact between sheep does not

seem to transmit BLV (Straub 1987b).

Unlike EBL, sheep do

not develop a PL stage unless in terminal stages of the
disease.

However, the LS stage is not always preceded by PL

(Dimmock et al., 1986; Djilali et al., 1987b).

Increased

numbers of PBLs in sheep are observed following BLV infec
tion.

These PBLs are not mature, but consist of 90-98%

lymphoblasts and, in most studies, signal the impending LS
stage and death within 1-5 months (Djilali et al., 1987b;
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Rogers et al., 1984).

However, Dimmock et al. (1986), found

prolymphocytes in BLV infected sheep 12-68 wks before death.
B-cell tumors are most often reported in sheep, though,
T-cell tumors have also been found (Burny et al., 1985a;
Levy et al., 1987).
Experimental transmission to goats, pigs, rats, rabbits,
monkeys, chimpanzees and buffalo has been reported (Portetelle et al., 1981; Ghysdael et al., 1984; Schodel et al.,
1986; Straub 1987b; Altanerova et al., 1989).

Rabbits in

fected by BLV die with high frequency of a wasting disease
reminiscent of immune deficiency (Burny et al., 1985b).
Since the documentation of the transmission of BLV to
non-human primates, exposure of man to BLV has been a con
cern.

In several surveys, negative results were obtained

when lab personnel, dairymen, veterinarians and abattoir
workers potentially exposed to BLV were screened for the
presence of BLV antibodies.

These surveys also found no

incidence of BLV antibodies in patients with various kinds
of leukemias or solid cancers (Olson, 1974; Devare, 1980,
Gilden et al., 1975; Straub, 1987b).

Recently, using BLV

probes and Southern blots, no involvement was shown in 157
human cases of acute lymphoblastic leukemia and non-Hodgkins
lymphoma or in 157 matched controls (Bender et al., 1988).
In in-vitro experiments in which BLV was transmitted to
human B-multiple myeloma cells only 2 of 60 clones screened
were found positive for BLV by Southern blot, and neither
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cell line produced viable virus or made normal BLV proteins
(Slavikova et al., 1987).

Thus, there is no evidence to

date that BLV can be transmitted to humans.
The Virus
The morphology of BLV is that of a type C leukemia virus
(Burny et al., 1985a).

It possesses an electron dense core

surrounded by a lucent area and is enclosed by a double
layered envelope which sometimes has surface projections.
Budding of BLV particles from the surface of lymphocytes is
rarely seen.

The particle is 90-110 nm in diameter and

contains a 60-80 nm core (Weiland et al., 1976).

It has a

buoyant density of 1.15 - 1.17gm/cm3 (Ferrer et al., 1980)
and has a 70s RNA, that is composed of two 38s dimers
(Ghysdael et al., 1984).

The complete 8714 nucleotide se

quence of BLV has been determined.

It encodes six

structural and three non-structural viral proteins (Sagata
et al., 1985b; Rice et al., 1987b).

As in all retroviruses,

it is flanked by long terminal repeats (LTR) and contains an
RNA-dependent DNA polymerase or reverse transcriptase (Burny
et al., 1985a).

BLV bears some serologic cross reactivity

to HIV, since rabbit anti-BLV antisera does react with
cultured lymphocytes of AIDS patients (Thiry et al., 1985).
However, it bears little homology to any other retrovirus
except HTLV-I, HTLV-II, and Simian T lymphotrophic virus-I
(STLV) (Oroszlan et al., 1982; Ghysdael et al., 1984; Burny
et al., 1987b).

These three viruses with BLV may compose a
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distinct family which replicate via trans-activation of
enhancer-promoter regions of their LTR* s and induce
pathologic changes in their hosts by similar trans-activa
tion of cellular genes (Rosen et al., 1985; Sagata et al.,
1985b).
The structural organization and protein-protein interac
tions of BLV have been determined by both electron micros
copy (EM) and chemical cross-linking studies (Uckert et al.,
1982; Mamoun et al., 1983b; Burny et al., 1985a).

BLV con

tains an outer membrane composed primarily of glycoprotein
(gp) gp30-gp50 dimers, which may be linked by disulfide
bridges.

Internal structural proteins exist as homologous

or heterologous dimers of p24, pl5, or pl2.

The two pro

teins pl2 and pl5 can also complex to RNA.
Coding Potential
There are three poly-A+ RNA species present by Northern
blot analysis of BLV-producing cell lines, a full size 9Kb
mRNA, a 5.1 Kb mRNA and a 2.1 Kb mRNA (Mamoun et al., 1985).
In vitro synthesis of BLV 38s RNA (9Kb mRNA) produced a 70
Kd group associated antigen precursor, precipitable by antip24 antibodies, which contains pl5, p24, and pl2 (core
proteins) and pl4, (a viral protease)
1979; Mamoun et al., 1983a, 1983b).

(Ghysdael et al.,
There is a second 45 Kd

precursor, also precipitable by p24, that lacks the pl4 pro
tease (Mamoun et al., 1983b; Burny et al., 1985a).

The

smaller polyprotein is not a cleavage product of the larger
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(Ghysdael et al., 1984).

The reverse transcriptase-endonu-

clease protein is made as a third 145 Kd gag-pol precursor
(Burny et al., 1987b).

No information on its cleavage is

available.
The 24s RNA (5.2 Kb mRNA) is a singly spliced message
coding for the envelope proteins gp50 and gp3 0 (Mamoun et
al., 1983b).

The glycosylated precursor of gp50 and gp30,

Pr72env, overlaps the 3' end of pol by 17aa.

Gp50-gp30

cleavage occurs at the Arg-X-Arg-Arg sequence found in many
viruses (Burny et al., 1985a, 1987b).

The unglycosylated

homolog of Pr72env, a 47 Kd polypeptide is not processed
further, as processing of Pr72env is glycosylation and con
formation dependent (Ghysdael et al., 1984; Burny et al.,
1987b).
The 16-18s RNA (2.1 mRNA) is a doubly spliced message
encoding two proteins, pl8 and p38 (Derse, 1987).

Ghysdael

et al. (1979) were the first to demonstrate the presence of
pl8 from in vitro translated 38s RNA in rabbit reticulocyte
lysates.
The LTR Region
BLV's 531 bp LTR has been compared to other retrovirus
LTRs, such as Moloney leukemia virus, simian sarcoma virus,
Rauscher leukemia virus, Gibbon-ape leukemia virus, baboon
endogenous virus and HTLV-I following sequence analysis.

No

significant homology between the BLV-LTR and the LTRs of
these other retroviruses has been found, however 50% homol

ogy has been demonstrated in a lOObp segment located in the
R regions of BLV and HTLV (Burny et al., 1985a; Sagata et
al„, 1984, 1985b; and Rice et al., 1987b).

The LTR is bound

by TG....CA and a perfect inverted repeat of 6 bases at both
ends.

Other general features include direct repeats (6bp)

of the host sequence at the provirus integration site, a
primer (tRNApro) binding site following the 5' LTR, and a
polyuridine tract (9bp) preceding the 3' LTR (Sagata et al.,
1984; Rice et al., 1987b).

The U3 region contains the puta

tive transcriptional promoters, the "CAT" and "TATA" boxes,
a polyadenylation signal site, and an enhancer region.

The

enhancer region shows 70% homology with the mouse immuno
globulin heavy chain gene enhancer, which functions in a Bcell-specific manner.
the cap site.

U3 is separated from the R region by

The exceptionally long R region (234 bp)

separates the poly A+ addition signal found in U3 from the
poly A+ site found at the 3' end of R by 260 bp.

The two

transcription termination sites are brought into close
approximation when the R region forms a large stable hair
pin structure on the nascent RNA chain, ensuring normal
termination.

This unique structural feature of the BLV LTR

R region is also seen in HTLV-I (Sagata et al., 1984).

Con

sensus splice donors for the variously spliced mRNA's (5.1kb
env and 2.lkb pX) can be found with an 8/9 match in the R
region of BLV, similar to HTLV-I (Rice et al., 1987b).

The

BLV and HTLV LTRs are type specific promoters, functioning

in only a very restricted set of cells.

The BLV LTR, when

linked to the chloramphenicol acetyltransferase (CAT) gene
functions only in BLV infected cells, indicating that BLV
produces a protein to regulate its own promoter activity via
the LTR (Derse et al., 1985; Derse and Casey 1986; Rosen et
al., 1985, 1986).

Derse (1986, 1987, 1988) used deletion

analysis to identify two sequences in the viral LTR that in
fluence gene expression and are acted upon in "trans" by pX
proteins, p38 and pl8, respectively.

These sequences, 5'

(75bp in U3) and 3 1 (250bp in R) to the RNA start site, act
as enhancers, functioning in either orientation.

However,

the 250bp sequence must be located downstream of the RNA
initiation site to function efficiently.
A 97 base untranslated region, following the 5" LTR, acts
as the primer binding site for tRNApro.

This region is short

when compared to Moloney-Murine Leukemia (M-MuLV) and Rous
Sarcoma virus (RSV), but longer than the analogous region of
HTLV-I which is only 26 bases (Rice et al., 1987b).
The Gag Gene
The gag gene is composed of 1179 nucleotides (Rice et al.
1985).

Uckert et al. (1984a) reported the translational

order of gag, as determined using pactamycin mapping, as
amino (NH2) terminal
(COOH) terminal.

plO -(plSj-plS,,) - p24 - pl2 - carboxy

The presence of plO as a viral structural

protein is still disputed.

Ghysdael et al. (1984), reported

plO was precipitated by BLV antibody positive sera from in

vitro translation mixtures using 38s RNA and from BLV in
fected cells.

Likewise, Yoshinaka et al. (1986) showed

cleavage of in vitro synthesized gag-related polyproteins
produced a myristylated plO, which was composed of the Nterminal part of pl5.
intact virus.

He also demonstrated its presence in

Rice et al. (1987b) do not mention the pres

ence of plO as a structural protein of BLV.

The (NH2)

terminal gag protein pl5 is myristylated via the Met-GlyAsn-Ser sequence typical of other retroviruses (Rice et al.
1987b).

It is a basic protein, the major virus phospho-

protein, and exists in two forms based on gel electrophor
esis (Burny et al., 1985a; Ghysdael et al., 1984).

One

population of pl5 exists linked to the lipid bilayer of the
viral membrane, and the other is linked to viral RNA
(Ghysdael et al., 1984).

It is similar to murine pl5 at its

N-terminal region, but its COOH-terminal end more closely
resembles avian pl2 (Rice et al., 1987b).
The first recognized and major BLV structural protein is
p24.

It consists of 215 amino acids, and shares the N-ter

minal proline and COOH-terminal leucine of the p30 of all
mammalian retroviruses (Ghysdael et al., 1984; Uckert et
al., 1984b).

Significant amino acid homology between BLV-

p24 and to HTLV-I p24 has been documented.

However, BLV-p24

is only distantly related to any other type C p3 0 proteins
(Gilden et al., 1975; Oroszlan et al., 1982; Ghysdael et
al., 1984;).

BLV pl2, located at the COOH-terminal end of
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the primary translation product of gag (Ghysdael et al.,
1984) is proline rich (Burny et al., 1985a), and binds
nucleic acids, a function that is homologous to the HTLV-I
pl5 (Rice et al., 1987b).

There is significant amino acid

sequence homology between BLV pl2 and HTLV pl5.
Significant, although less, homology with avian and
mammalian type C viral proteins has also been documented
(Rice et al., 1987b).
Viral Protease
The viral protease, pl4, is coded from a 585 nucleotide (NT)
open reading frame (ORF) overlapping the 3' end of gag on
its 5' end and overlapping the pol gene at its 3 1 end (Rice
et al., 1985).

However, the protease amino acids do not

overlap, as 38 codons on the 5' end and 26 codons on the 3'
end of its mRNA are not included in the final protein pro
duct (Yoshinaka et al., 1986).

Several lines of evidence,

such as protein mapping of the gag polyprotein precursor,
the characteristic structure of the mRNA, and promotion of
the synthesis of a gag polyprotein precursor by lysine tRNA
in vitro, suggest that the protease could be translated by
frameshift suppression of the gag termination codon (Yosh
inaka et al., 1986).

BLV protease has sequence homology

with the viral proteases of the avian and mammalian type C
virus sequences over its entire length, and is most closely
related to murine protease demonstrating a 30% match in
nucleotide identities (Yoshinaka et al., 1986; Rice et al.,
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1987b).

Most retroviral proteases resemble a single domain

of an aspartic protease and function in a dimeric form to
cleave the gag and gag-pol polyprotein into those proteins
found in the mature virion (Yoshinaka et al., 1986; Pearl
and Taylor 1987; Rice et al., 1987b).
Reverse Transcriptase and Endonuclease
The reverse transcriptase is an 852 aa protein, MW
70,000,

(Burny et al., 1980) and is the most conserved of

the BLV structural genes (Sagata et al., 1985b).

From

residue 5 all the way to the C-terminus of the predicted
protein, the BLV sequence is highly homologous to that of
HTLV with 47% identical residues (Rice et al., 1987b).

Sig

nificant homology to murine and avian genomes has also been
demonstrated (Sagata et al., 1985b).

The 3' end overlaps

the 5' end of the env gene, as in M-MuLV and RSV, and con
tains the splice acceptor sequence used in the production of
both the 5.1 mRNA of env and the 2.1 mRNA of the pX proteins
(Derse 1987; Rice et al., 1987b).

Mechanisms of translation

of the pol gene are not yet known but there are termination
codons at the end of the gag, protease and RT genes in three
different reading frames (Rice et al., 1985, 1987b).

BLV RT

function is dependent on RNA and all 4 deoxyribonucleoside
triphosphates (Ghysdael et al., 1984).

Unlike the RT of

most type C viruses which are dependent on Mn++, BLV RT
strongly prefers Mg++ (Weiland and Ueberschar, 1976; Gilden
et al., 1975).
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The Envelope Gene

The envelope gene codes for gp51, 268 AA, MW 30,572 and
gp30, 214 AA, MW 24,082 (Rice et al., 1984).

The 5' portion

of the gene contains the splice donor needed for the produc
tion of the 2.1 kb mRNA coding for pX proteins (Rice et al.,
1987a).

The BLV and HTLV-I large envelope proteins have a

number of structural similarities (Rice et al., 1987b; Burny
et al., 1985a).

BLV gp51 contains 8 potential glycosylation

sites, while gp30 contains only two (Sagata et al., 1985b).
BLV gp30, typical of type C transmembrane proteins, has both
NH2 and C-terminal hydrophobic areas and of its six cysteine
residues, four are conserved in all type C viruses.

It

shares 36% homology with HTLV-I p30 env (Rice et al., 1984;
Schultz et al., 1984).
The Post Envelope Region

There are 1817 bases between the env gene and 3' LTR of
BLV, containing three ORFs (Burny et al., 1985a).

This area

has similar genomic structure to both HTLV-I and II and a
similarity in distribution of hydrophobic and hydrophilic
regions in HTLV and BLV peptides (Haseltine et al., 1984).
Two non-structural proteins pl8 and p38, translated from a
doubly spliced 2.1kb mRNA, from two ORF's have been iden
tified (Sagata et al., 1985a; Rice et al., 1987a).

The key

sequences used for splicing the 2.1Kb mRNA in BLV are simi
lar to sequences found in HTLV-I,-II, and STLV (Willems et
al., 1987).

Translation of pl8 initiates from the first AUG

of env and proceeds through the pX SORF, while p38 initiates
from the second env AUG and proceeds through the pX LORF
(Rice et al., 1987a).

The phosphoprotein, pl8, contains 17

AA of the env signal peptide and the remainder is coded from
the pX to produce a 156 AA protein which is high in proline
and serine content (Rice et al., 1987a).

Both p38 and pl8

act to increase the production of BLV structural proteins,
acting in "trans" on specific sites of the LTR.

P38, with a

half life of only 6 hours, localizes in the nucleus of BLV
infected cells (Sagata et al., 1985a).

Production of full

length (9kb) and env (5.1kb) mRNA's requires expression of
both p38 and pl8 (Derse, 1988).

The 75 bp region of the LTR

acts as a p38-dependent enhancer element, while the pl8 is
required for the accumulation of the 9 and 5.1 kb messages
and acts on the stem loop structure found in the long R
region of BLV (Derse, 1987).

P18 may act to stabilize this

structure and result in the accumulation of viral message in
infected cells (Derse, 1988).

Itohara (1988) demonstrated

trans-activation using LORF or SORF plasmids transfected
into cells containing the BLV LTR spliced to the env gene.
He found p38 was the major trans-activator, however, pl8 can
enhance this activity 5 fold.
BLV Production and Cell Culture Systems
Short Term Cultures
BLV was first identified by EM visualization of type-C
particles in PHA stimulated lymphocytes from LS cattle

(Miller et al., 1969).

Ferrer et al. (1972) confirmed these

results using cell cultures from PL cattle and leukemic cow
serum in immunofluorescence assays.

Stock (1972)

demonstrated that viral budding could take place as early as
3 hours post culture.

All three investigators could detect

BLV in cultures with or without PHA stimulation and Stock
deduced in vitro maintenance of cells and not PHA stimula
tion was responsible for the expression and/or replication
of the virus.
Gupta and Ferrer (1982) and Gupta et al. (1984) reported
expression of BLV in short term cultured lymphocytes is
blocked at the transcriptional level by a non-immunoglobulin
protein present in the plasma but not in the serum of BLVinfected cattle.

The effect of this plasma blocking factor

(PBF) on the production of BLV by lymphocytes in short term
cultures is reversible.

PBF is also found in BLV infected

sheep, but varies between and within animals depending on
time of collection (Cornil, 1989).

Tsukiyama et al. (1987)

demonstrated that platelet derived factors (PDF) obtained
from platelet lysates of both BLV positive or negative
cattle could inhibit the effect of PBF.

This effect, unlike

that of PBF is irreversible, once added to lymphocytes, PDF
will induce the continued production of BLV even if PDF is
subsequently removed and PBF is added.

The mechanism of

action of PDF is not known, however, several factors such as
platelet-derived growth factor (PDGF) and transforming

growth factor (TGF)-/3, are contained in high titer in plate
lets.

These factors have mitogenic activity, as does PHA,

and are significantly related to the regulation of cell
cycles (Tsukiyama et al., 1987).

Takashima and Olson (1981)

demonstrated production of BLV is indeed dependent on cell
cycle and that the development of BLV in lymphocytes
requires infected cells to enter the cell cycle from the
resting stage.
Exogenous factors produced by T-cells can also induce the
expression of BLV in short term cultures.
(1977)

Paul et al.

were the first to recognize that although B-cells

produce BLV, more cells produced virus in mixed cultures of
PBL than in nylon wool enriched B-cell cultures.

They found

PHA, a T-cell mitogen, increased virus production in puri
fied B-cell cultures.

Similar experiments, with various

mitogens, were conducted in sheep to further support the
idea that T-cell factors in some way trigger the transcrip
tion of BLV in B-cells (Djilali et al., 1987a; Levy et al.,
1987; Cornil et al., 1988).

Levy et al. (1987) found that

BLV expression was not linked to PHA induced B-cell multip
lication, but as demonstrated by Cornil et al. (1988) did
correlate with the proportion of T-cells present in the cul
ture.

All three investigators demonstrated conditioned

media prepared from PHA stimulated normal lymphocytes great
ly enhances BLV production in short term cultures of puri
fied B-cells.

Djilali et al. (1987a) postulated that PHA

stimulates T-cell factors which act on the BLV enhancer to
initiate BLV production in a limited number of specific Bcell clones, accounting for the in vivo presence of high
levels of viral antibodies.

Chatterjee et al. (1985) demon

strated that PHA activation of transcription of the BLV
genome required de novo protein synthesis, however, the
cells producing this protein were not identified.

Perhaps

inhibition of T-cell triggering is the method of repression
by the above mentioned PBF.

If PBF or some other factor

found in BLV positive cows does inhibit T-cell triggering in
vivo, then BLV positive cow sera should inhibit lymphocyte
function in vitro.

Cornil et al. (1988) demonstrated that

PBF not only blocked production of p24 in both PHA stimu
lated or unstimulated lymphocytes, but could also decrease
the normal proliferative response of lymphocytes from either
BLV infected or uninfected cattle.

Takamatsu et al. (1988)

showed inhibition of the growth of IL-2 dependent bovine Tcells and mitogen induced blastogenesis by PHA, Con-A, PWM,
LPS and protein-A by sera from BLV positive cows.
Long Term Cultures
Van Der Maaten et al. (1974) developed a persistently
infected fetal lamb spleen (FLS) cell line by co-culture
with cells from BLV infected PL and LS cows.

The amount of

virus produced was increased by switching from FLS to fetal
lamb kidney (FLK) cells (Van Der Maaten and Miller 1975a).
Graves and Ferrer (1976), using similar co-culture tech-
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niques, developed a persistently infected bat lung cell
line.

The bat and kidney cell lines supply most of the BLV

used in laboratory research today.

However, other cell

lines have been produced or "BLV transformed" for experimen
tal purposes (Mamoun et al., 1981; Onuma et al., 1981b;
Mamoun et al., 1985; Onuma et al., 1986; Burny et al.,
1987b; Slavikova et al., 1987; Altanerova et al., 1989).
Characteristics of BLV Infected Cells
The majority of circulating lymphocytes from PL cattle
are primarily B-lymphocytes; however, the proportion of Blymphocytes increases appreciably before any detectable
increase in the total number of circulating lymphocytes is
seen (Burny et al., 1987b).

The number of B-lymphocytes

increases from 28% in normal cows to 63% of the total lymph
ocytes in PL cows (Muscoplat et al., 1974b).

These results

were obtained by a large number of investigators using a
variety of labeling techniques:

Anti-slg, anti-Fc receptor,

anti-thymus serum or PNA and immunofluorescence, spontaneous
SRBC rosetting, monoclonal or polyclonal B or T-cell anti
bodies and various lectins (Muscoplat et al., 1974b; Mayr et
al., 1982; Koyama et al., 1983; Gershwin et al., 1983; Mikalauskine et al., 1984; Esteban et al., 1985; Fossum et al.,
1988; Williams et al., 1988b).

Recent studies show that the

induction of BLV by short term culture may influence the
regulation and expression of slg and BoLa class II antigens
(Burny et al., 1987b).

Several investigators found cells
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doubly labeled with both T and B-cell markers.

Fossum et

al., (1988), found PL cells reacting with both B and T-cell
lectins and attributed it to altered sugar compositions
found on the cell surface.

Williams et al. (1988b) and

Depelchin et al. (1989) both found a population of slg+ Bcells in BLV infected cattle that also react with T-cell
monoclonal antibodies.

Depelchin et al. (1989) found this

population of doubly labeled cells increases in proportion
to the increased number of total peripheral lymphocytes in
PL animals.
Although the majority of the PBL in BLV infected cattle
are B-cells, increases in T-lymphocyte numbers have been
noted (Dimmock et al., 1986; Burny et al., 1980; Williams et
al., 1988b).

Similarly, T-lymphocytes containing the BLV

genome have been found and these cells are capable of pro
ducing BLV antigens during short term lymphocyte cultures
(Burny et al., 1980; Williams et al., 1988a).
A small percentage of the Ig bearing cells are enlarged,
seem to be arrested at an early stage of maturation, and
show an increase in the intensity of fluorescence when
labeled with anti-sIgM.

Burny hypothesized that factors

that effect the BLV enhancer in "trans" to increase its ex
pression may also increase slgM via stimulation of the Ig
enhancer region (Burny et al., 1987b).
The mean lymphocyte response to PHA and PWM, as indicated
by the degree of 3H-thymidine incorporation was markedly

less for lymphocytes obtained from cows with PL than for
those obtained from normal cows (Muscoplat et al., 1974a).
They also observed lymphocytes from PL cows incorporated
approximately 5 times more tritiated thymidine than did
lymphocytes from normal cows when cultured without phyto
mitogens.

Similar lectin results were obtained by Djilali

et al. (1987b) using sheep lymphocytes.

Density gradient

centrifugation techniques were used to separate B-cells from
a PL cow into a subpopulation that is infected with BLV and
a noninfected subpopulation that spontaneously incorporates
3H-thymidine after 3 days in culture (Kenyon and Piper
1977a, 1977b).

The latter population, unlike the malignant

lymphocytes that are found in the blood of cattle with
lymphosarcoma, are sensitive to glucocorticoids, both in
vitro and in vivo.

Bloom et al. (1979), after in vivo

steroid treatment of PL cattle, found an 80-90% decrease in
the B-cell population, most of which were those that spon
taneously incorporated 3H-thymidine.

The activity of these

cells can be specifically inhibited in vitro by sera con
taining BLV antibodies indicating these cells may be respon
sive to the presence of BLV antigens (Ferrer et al., 1979).
Jacobs et al. (1981) using a nonstructural antigen isolated
from tumor cells could cause in-vitro blastogenesis of
lymphocytes from 69% of LS cattle but only 4% of normal
cattle.
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Weber et al. (1969) saw an increased frequency in the
presence of nuclear pockets in lymphocytes of PL and LS
cows.

The presence of these nuclear pockets, seen by EM,

correlated well with the ability of these cells to produce
C-type particles when cultured with PHA.

However, the per

cent of BLV infected cells varies from animal to animal and
within one animal, especially if lymphosarcoma develops
(Burny et al., 1980).
The diagnosis of tumorigenicity of circulating lympho
cytes or LS cells depends primarily on morphologic and
karyotypic findings.

Most cases of PL result from a benign

proliferation of B lymphocytes; however, in LS cases chromo
somal ploidy is common (Hare et al., 1967).

These

chromosomal changes vary from animal to animal, but also
within an individual if more than one LN is examined.

The

same cell line is found in each case, suggesting a
unicentric tumor origin with metastasis (Burny et al.,
1987b).
Onuma et al. (1977) has taken a different approach and
looked for tumor associated antigens (TAA) on the surface or
in the cytoplasm of various cells from BLV infected cattle
and sheep.

TAA was expressed in 15/15 LS cattle, 5/5 LS

sheep, 3/15 AL cattle and 1/7 healthy BLV positive sheep.
In the 3 positive AL cattle, a B-cell population above the
average for the other 12 cattle was noted.

This indicates a

possible relationship between increased B-cell percentage
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and the appearance of TAA.

Onuma et al. (1981a), produced a

transformed sheep fibroblast cell line by co-culture with
BLV.

The major surface protein expressed on this new cell

line, SF-28, was a nonstructural protein while that express
ed on FLK cells was the structural protein gp50.

Later in

1987, at the 107th passage of SF-28 cells, they discovered
only 0.6% of the cells expressed BLV structural antigens
while 60-70% expressed a non-structural antigen (Onuma,
1987) .

Monoclonal antibodies against TAA identified a 41Kd

protein using Western blot assays.

Circulating anti-TAA

antibody was found in 8/81 AL, 13/14 PL, and 14/14 LS cattle
and 4/4 BLV infected but healthy sheep.

Two of these sheep

became negative for p41 antibody one to three months before
death, however, antibody to gp51 and p24 remained constant.
Aida et al. (1985a, 1985b) has divided TAA into 3 groups
based on reactivity with a panel of monoclonal antibodies:
1) common TAA (MW 74kd) found on all tumor cells, 2) par
tially common TAA found on some tumor cells (MW 64Kd) and 3)
individually distinct TAA (MW 64Kd).

Although Onuma and

Aida work together, no correlation with the p41 protein
found by Onuma was mentioned.
BLV Provirus
Kettmann et al. 1978 demonstrated BLV was an exogenous
oncogenic RNA virus using BLV cDNA as probe.

LTR sequences

flank the provirus which is covalently linked to GC rich
regions upon integration into the host cell genome (Kettmann
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et al., 1979).

In sheep the provirus can be found as unin

tegrated linear molecules in circulating lymphocytes (Burny
et al., 1985a).

Sites of BLV integration are not rearrang

ed, are not similar to known oncogenes, nor does BLV seem to
influence transcription of cellular flanking sequences (Gelmann et al., 1984).

Burny et al. (1985a) found minimal

variation of the provirus among BLV strains derived from
cattle in different countries using restriction enzyme (RE)
analysis.

Provirus can be found in PBL or lymphoid tissue

of all BLV infected animals and in solid tumors and tissues
infiltrated with tumoral lymphoid cells, but not in normal
organs of LS animals (Kettmann et al., 1978; Ferrer et al.,
1980).

Polyclonal proviral DNA integration (at a large

number of genomic sites) is seen in less than 5% of the PBL
in AL cattle, but from 25-40% in PL animals.

However, in

tumors, monoclonal integration (at one or very few sites) in
the majority of cells is found (Kettmann et al., 1979,
1980a, 1980b, 1981).

Although bovine tumors are monoclonal

populations of cells, the integration sites between tumors
are not conserved.

Using hamster X bovine somatic cell

hybrids and probes made from unique cellular fragments ad
jacent to single copy proviruses, Gregoire et al. (1984)
showed BLV integrated in three different chromosomes in
three separate tumors, demonstrating that leukemogenesis by
BLV is independent of proviral site of integration.

BLV-

induced tumors can contain proviral genetic information, up

to four copies per ceil, demonstrating the indispensable
presence of the virus for tumor development.

However,

whether unique or multiple, about 1/4 of the number of pro
viral copy or copies found may contain deletions (Kettmann
et al., 1982; Burny et al., 1987b).

Tumors with a single

deleted copy of the genome are known, but it appears that
all tumors carry the 5 1 LTR and the 3' portion of the pro
virus (Kettmann et al., 1982; Mamoun et al., 1985; Onuma et
al., 1986; Ogawa et al., 1987).

This implies pX trans-

activating proteins may be involved in tumor induction.
They could be involved in the trans-activation of host
factors leading to an irreversible cascade of events that
results in tumor induction.
Regardless of where the provirus is integrated, BLV is in
a repressed state, with extremely low or no viral RNA or
proteins detected in vivo (Ferrer et al., 1980; Portetelle
et al., 1981; Notzel et al., 1982; Kettmann et al., 1982,
1985; Burny et al., 1985a).

Ferrer et al. (1980) found no

difference in the number of proviral DNA copies in PBL of AL
versus PL cattle when they compared them before and after in
vitro culture.

However, they did find significant amounts

of RNA present after in vitro culture, demonstrating the
genome must be repressed at the transcriptional level in
vivo.

Burny et al. (1987b) grew four bovine and two ovine

tumors in vitro and found only 2 expressed viral antigen
while four had no detectable viral RNA or viral proteins.

Probes from the conserved 3' pX region also do not detect
significant viral message in some cultured tumor cells
(Kettmann et al., 1985).

Altanier et al. (1987) found non

producer FLK-BLV cell lines which do contain a full length
proviral copy.

Assuming these tumors were all induced by

BLV, it seems the virus is necessary as an inducer of the
neoplastic process but is dispensable once the process is
switched on.

Burny et al. (1985b) hypothesized that after

transformation of the infected cell, extinction of provirus
expression is a mandatory step allowing the neoplastic cell
to escape immune surveillance while proliferating.

However,

continual production of antibody, in the absence of further
exposure to virus, indicates that some mechanism for antigen
expression must be operational, because antibodies do not
persist in cattle immunized with killed virus (Miller and
Van der Maaten, 1980).
Detection of BLV Infection
The earliest diagnostic test for BLV was based on the
presence of increased lymphocyte counts and various leukosis
keys were proposed and used (Straub 1987a).

Many BLV diag

nostic tests have been used, some of the earliest were
complement-fixation (CF) (Miller et al., 1974), rapid syn
cytia induction (SIA) (Diglio and Ferrer 1976, Ferrer and
Diglio 1976), radioimmunoprecipitation (RIP) (Devare et al.,
1977; Schmerr and Goodwin 1981a), virus neutralization (VN)
(Ferrer et al., 1977) and agar gel immunodiffusion (AGID)

using p24 as antigen (Miller et al., 1974).
(1978)

Straub et al.

compared the use of either p24 or gp50 as antigens in

AGID assays.

The majority of cows tested produced antibody

to both p24 and gp50, however, a small number produced
detectable antibody to only gp50.

By 1980, the AGID test

had been standardized using both gp50 and p24 (Committee on
Bovine Leukemia Virus, 1980).

Because of its increased sen

sitivity and ease of use, the AGID soon became one of the
most popular diagnostic assays (Burny et al., 1980).

The

enzyme-linked immunosorbent assay (ELISA), using cell supernates containing BLV or purified gp as antigen showed
similar results to those obtained for the gp50 - p24 AGID;
however, quantitative results could be obtained with the
ELISA system (Todd et al., 1980, 1982? Poli et al., 1981;
Graves et al., 1982).

Several labs compared the various BLV

detection methods (Devare et al., 1977; Ferrer et al., 1977;
Kaaden et al., 1978; Bex et al., 1979; Mammerickx et al.,
1980; Miller et al., 1981; Poli et al., 1981; Graves et al.,
1982; and Djilali et al., 1987b).

All sampling techniques

were not used by each investigator, nor did all
investigators obtain consistent comparisons.

However, for

the positive detection of BLV antibodies in the sera of BLV
infected cattle most indicated RIA using gp51 > RIA using
p24 > VN = SIA > AGID = ELISA > Fab = EM.

There was a 96%

or greater agreement between all testing methods used except
Fab and EM, which were used only in the very earliest tests.

Most discrepancies appeared when the antibody titer was very
low.

One of the most sensitive and easiest ways to screen

large numbers of both serum or milk samples and be as ac
curate as RIA without the use of radiolabelled materials is
the anti-gp50 monoclonal ELISA.

The anti-gp50 antibody,

attached to the ELISA plate, binds to BLV obtained from a
crude prep of clarified supernates from BLV infected cells.
This method is more sensitive than the more widely used AGID
to screen large numbers of sera (Portetelle et al., 1983,
1987, 1989c; Mammerickx et al., 1984; Florent et al., 1988).
Western blots using whole virus as antigen were used by
Deshayes et al. (1977), Walker et al. (1987) and Heeny et
al. (1988) to detect BLV antibodies.
BLV Serum Antibodies
BLV infected cattle have been found to possess antibodies
to at least six structural (gp50, gp35, p24, pl2, pl5, RT)
and two nonstructural proteins (pl8, p38).

However, the

presence of antibodies to the various proteins is dependent
on the stage of disease progression (Heeny et al., 1988; Wu
et al., 1977; Deshayes et al., 1977, 1980; Portetelle et
al., 1981; Willems et al., 1987, 1988).

Viremia can be

monitored only the first 10-12 days post infection, preced
ing the appearance of virus neutralizing antibody (Burny et
al., 1987b).

Anti-gp50 antibodies appear 2-4 weeks post in

oculation in both sheep and cattle, followed closely by the
appearance of p24 antibodies (Miller and Van Der Maaten

1975; Portetelle et al., 1981; Cockerell et al., 1986; and
Djilali et al., 1987b).

Most surveys demonstrate a steady

rise in antibody titers with disease progression in both
sheep and cattle (Ferrer et al., 1974, Bex et al., 1979;
Mammerickx et al., 1980; Kono et al., 1981; McGuire et al.,
1981; Portetelle et al., 1978, 1981; Thurmond et al., 1985;
Heeny et al., 1988).

However, there are large individual

variations, especially in sheep, and antibodies to BLV do
not seem to influence disease progression or fatal onset of
the tumor phase.

Variations in antibody titer that were

significant enough to alter the classification of animals
from positive to negative or negative to positive were seen
in 36/254 cattle tested over a four year interval (Kaaden et
al., 1978).

This may be explained in part by the finding of

Burridge et al. (1982), who reported a significant fall in
antibody titer occurred in cattle at the time of calving
with a subsequent rise within one month.

They theorized the

titer decrease was due to passage of circulating antibodies
into the colostrum.

Bex et al. (1979) found p24 and gp51

antibodies present in milk, although at much lower levels
than in serum.
Although the presence of circulating antibodies remains
high, the significance of antibodies against individual
proteins has not yet been determined.

Kono et al. (1981),

McGuire et al. (1981) and Thurmond et al. (1985) observed
higher titers to p24 in LS cattle than in "clinically"
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normal BLV positive animals, suggesting a relationship
between increased p24 antibody and malignancy.

Similarly,

Heeny et al. (1988) found sero-positive cattle with lymphoma
reacted to more BLV antigens than infected healthy cattle as
determined by Western blot analysis.

All sero-positive

cattle reacted with p24 and gp50; clinically normal sero
positive cattle reacted only occasionally with plO and pl2,
and less than half the time with gp35; while LS cattle had
high titers to plO and pl2, and most reacted with variable
intensity to gp35.

In an earlier study, Deshayes et al.

(1980) using RIP, reported similar results, however, she
attributed these findings to quantitative differences in
antibody titers found between non-LS and LS cattle.

Heeny

et al. (1988), however, saw no consistent relationship bet
ween cases with higher antibody titers and the number of BLV
antigens identified using ELISA and Western assays.
Antibodies directed against BLV are usually of the IgG1
and IgA subclasses (Burny et al., 1980; Heeny et al., 1988).
Infection of cattle with BLV appears to affect the synthesis
or release of IgM as evidenced by lower than normal levels
found in serum of PL and LS animals.

The IgG levels seem to

remain constant (Trainin et al., 1981; Meiron et al., 1985;
Heeny et al., 1988).

In sheep, an absence of any non

specific immunosuppressive effect of BLV was demonstrated by
analysis of serum IgG concentrations, immunization with
rabbit RBC and skin testing (Cockerell et al., 1986).

In PL
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cattle and LS sheep, BLV does have the specific immunosup
pressant effect of decreasing natural cellular cytotoxicity
of lymphocytes against FLK-BLV cells (Yamamoto et al., 1984,
1985).
Portetelle et al. (1978) demonstrated an increase in
complement dependent antibody cytoxicity (CDAC) which paral
leled an increase in anti-BLV titer in sheep, even after the
onset of the LS stage.

Contrary to this, two later studies

demonstrated CDAC against FLK-BLV cells did not increase
with time (Honma et al., 1980; Schmeer et al., 1981b).

CDAC

is directed against gp50, the important antigenic epitopes
of which are carbohydrate (CHO) moieties (Portetelle et al.,
1981; Schmeer et al., 1981b).

Tunicamycin treatment of FLK-

BLV target cells, reduced the CDAC response found using BLV
positive cow sera by 80% to 30%.
BLV gp50 was characterized using a panel of 15 monoclonal
antibodies developed by Bruck et al. (1982a, 1982b, 1984).
Out of eight antigenic sites recognized, four were conformationally dependent (C, F, G, H) and three (F, G, H,) were
biologically significant.

The latter mediated infectivity,

syncytia induction and acted as the targets of CDAC activity
found in sero-positive cows (Burny et al., 1985b; Portetelle
et al., 1989c).

Reactivity against these CDAC epitopes is

dependent upon both conformation and glycosylation.

Epi

topes F, G, and H are absent from tunicamycin treated FLKBLV cells which produce unglycosylated gp50 (Schmerr et al.,

1981b), and treatment of gp50 with SDS and 100"C heat will
totally destroy their reactivity with cattle serum (Burny et
al., 1985b).

Portetelle et al. (1989a, 1989b, 1989c),

located epitopes F, G, and H at the N-terminal region of
gp51, from AA 35 to 95.

Surprisingly, variations in the

three epitopes are not rare and viral mutants lacking one or
two of these epitopes are known.

However, no variant lack

ing all three epitopes has been found.
Most recently, antibodies to the pX nonstructural pro
teins have been demonstrated in various BLV infected cow
sera.

Willems et al. (1987, 1988) and Burny et al. (1987a)

expressed cDNA clones corresponding to the LORF of BLV in
various expression systems to produce the "trans" acting
protein p34 (p38).

Reactivity to p34 (p38) was found using

sera from cattle in the LS stage and practically all sera
from BLV infected sheep.

Yoshinaka et al. (1985) expressed

a 14kd protein corresponding to the SORF of BLV and found it
reacted with 2/11 LS cow sera tested.

As previously stated,

the 3' end of the BLV genome encodes the pX proteins and is
conserved in all tumors analyzed to date.

The induction

and/or maintenance of the tumor stage by the expression of
px would account for an increased proportion of px positive
sera during this LS stage.

Expression of pX proteins may be

kept at a minimum by host regulatory factors during early
stages of the disease, but due to unknown causes be dere
pressed thus inducing the tumor phase.

Burny et al. (1985a)
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discusses the presence within a 150bp region of pX of 4
identically spaced oligomers in both BLV and HTLV-I.

The

lack of third base changes in these oligomers, which would
be expected in bases encoding conserved amino acids, tends
to suggest these sites may function in a regulatory manner.
Perhaps regulation via these sites limits the expression of
p38 and pl8 during earlier stages of disease.
Vaccination
Lambs harboring maternal passive antibodies are fully
protected against challenges with massive amounts of BLV
infected cells.

However, as passive antibody titers dropped

to low values, animals became fully sensitive to the chal
lenging infectious material (Burny et al., 1985c).

It seems

safe to assume, then, that vaccination using the appropriate
antigen or antigenic epitopes might well be protective.
Recent vaccine production has centered around the use of
gp50 antigenic epitopes in a form recognized by the animal.
These vaccines include the use of gp50 ISCOMS (Merza et al.,
1989); a recombinant Vaccinia virus containing the gene for
gp50 (Ohishi et al., 1988) and KLH conjugated synthetic
peptides of the N-terminal portion of gp50 (Portetelle et
al., 1989b).

Further research may well find the answer to

prevention of both BLV and its closely related relatives
HTLV I and II, and STLV.
There is a lack of information on the correlation of the
humoral immune response of BLV infected cattle, with BLV

induced clinical findings.

While increased reactivity to

many BLV proteins seems to be found in advanced stages of
the disease, random surveys cannot be used to correlate this
antibody response data to the time of transition from one
state (such as AL) to a second state (such as PL).

Also,

most studies have reported anti-p24 or gp50 antibody produc
tion and have not followed the production of antibody to all
structural and non-structural BLV proteins.

The importance

of the presence of anti-pX antibodies to the progression of
EBL is unknown at present.

However, the idea that these

proteins can be expressed on the cell surface and thus can
become a target for both humoral or cell mediated immune
responses is supported by their presence.

Further inves

tigation into both of these areas needs to be conducted.
This study was designed to address these questions by
obtaining sequential serum samples from BLV positive cattle
following a planned infection.

The developing immunological

response of BLV infected cattle to various BLV proteins can
then be correlated with disease progression based on the
progressive accumulation of clinical data.

Chapter II
Evaluation of Western Immunoassay for Detection
of Bovine Leukemia Virus Proteins.
Introduction

Bovine Leukemia Virus (BLV), a type C exogenous
retrovirus is the etiologic agent of Enzootic Bovine
Leukosis.

It can induce a benign lymphoproliferative

disease in infected cattle, which, with time, may progress
to a lymphosarcomatous stage (Miller and Van der Maaten
1980).

Animals develop a humoral immune response within

weeks following BLV infection.

The major response is

against the envelope protein gp50 and the core protein p24,
however, antibody against other viral structural proteins
(gp30, pl5, pl2, plO) and the nonstructural proteins (pl8
and p38) has been reported (Deshayes et al., 1977, 1980;
Portetelle et al., 1978; Mamoun et al., 1983a; Sagata et
al., 1985a; Yoshinaka et al., 1985; Heeny et al., 1988).
Many studies have attempted to characterize the humoral
immune response of BLV infected cattle (Ferrer et al., 1974;
Bex et al., 1979; Mamerickx et al., 1980; Kono et al., 1981;
McGuire et al., 1981; Portetelle et al., 1981).

The agar

gel immunodiffusion (AGID) test is the most widely used test
to diagnose BLV (Burny et al., 1980).

The AGID detects

antibody to gp50 and is simple to use, but has limited
sensitivity. A radioimmunoassay (RIA) detects antibody to
gp50 or p24, is very sensitive, but requires radiolabelled
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antigen (Mammerickx et al., 1980).

An enzyme linked

immunosorbent assay (ELISA) uses partially purified BLV as
antigen, but high background staining associated with bovine
sera interferes with interpretation of the results in many
cases (Todd et al., 1980, 1982; Portetelle et al, 1983,
1987).

A more sensitive gp50 antigen capture ELISA is

available, but this requires monoclonal antibodies against
epitopes of gp50 that do not interfere with the binding of
bovine antibodies (Mammerickx et al., 1984; Portetelle et
al., 1989c).

Western blotting procedures have also been

published, but do not always adequately detect the presence
of viral proteins especially the envelope glycoproteins
(Walker et al., 1987; Heeny et al., 1988).

We have

developed a simplified Western immunoassay to detect antibovine immunoglobulin to all the BLV structural proteins.
We used this system to follow the development of the humoral
immune response of 12 cattle experimentally infected with
BLV and compare this detection method with AGID and ELISA
assays.
Materials and Methods
Serum Samples and Monoclonal Antibodies
Serial serum samples were taken from 12 cattle over a
two year period following experimental infection with BLV.
Twenty-five samples per cow were obtained for a total of 300
samples.

Inoculation and characterization of these cattle

(6 AL and 6 PL) has been described (chapter 3).

Monoclonal
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antibodies for use as controls in the detection of gp50 and
p24 have been characterized elsewhere (Chapter 4).
Antigen Preparation
Antigen was prepared from pelleted supernate of BLV
infected or uninfected FLK cells (Van der Maaten and Miller
1975a; Freshney, 1983; Chapter 3).
Agar Gel Immunodifffusion
All serum samples were tested for precipitating
antibodies to commercially prepared BLV glycoproteins using
the standard AGID test (Leukassay-B, Pittman-Moore Inc.,
Washington Crossing, NJ).

This antigen preparation contains

BLV-gp50 and a small amount of p24.

Antibody reactivity was

classified as very weak, weak or positive depending on the
positions of the precipitation line.
ELISA Assays
ELISA assays using partially purified (pelletted) BLV
as antigen were preformed as described (Todd et al., 1980,
1982; Chapter 3).

Serum samples were tested at dilutions of

1:50, 1:100 and 1:200.
Western Blots and Immunodetection
Proteins of pelletted BLV were separated on 12% non
denaturing gels using a modification of the technique
described by Hames and Rickwood (1981).

Neither the

stacking nor separating gels contained SDS.

Samples

(800ug/gel), after dilution in sample buffer (0.05M Tris-HCl
pH 6.8, + 10% glycerol + Bromophenol blue + 0.1% SDS), were

applied to each gel and electrophoresed at 4 watts for ap
proximately 4 hours.

At the completion of the run, the gels

were transferred to nitrocellulose paper in ethanolamine
transfer buffer [4.6ml ethanolamine (Sigma, St. Louis, MO) +
5.6g glycine (Bio Rad laboratories, Richmond, CA) + 500ml
MeOH + 2500ml dH20] with a Bio Rad Trans-Blot apparatus (Bio
Rad Laboratories, Richmond, CA) at 75 volts for 2 hrs (Towbin et al., 1979).

To ensure proper transfer of proteins,

gels were stained with Coomassie Brilliant Blue [0.2%
Coomassie Brilliant Blue 250 (Bio Rad laboratories, Rich
mond, CA) dissolved in 50% methanol-dHzO plus 7% glacial
acetic acid] and the nitrocellulose paper was stained with
Ponceau S [0.5% Ponceau S (Sigma, St. Louis, MO.) in 1.0%
acetic acid].

Nitrocellulose paper was dried in a vacuum

oven overnight (34°C) and cut into strips.
The nitrocellulose membrane strips were rinsed on a
rocking platform in 150 mM NaCl, lOmM Tris-HCL pH 7.4, (TBS)
for 5 minutes, blocked for 1 hr in a skim milk solution
(similar to BLOTTO [Johnson et al., 1984], marketed by Bio
Rad Laboratories, Richmond, CA with their HIV immunoblot
detection kit #1971009, a gift from Dr. Ruth Kibler) and
incubated overnight with bovine serum diluted 1:200 in the
same blocking solution.

Serum was removed by three five

minute washes, two with 1M NaCL + 0.05% Tween followed by
one with 1M NaCL.

Peroxidase conjugated goat anti-bovine

IgG (H&L) (Pel-Freez, Rogers, AK) 1:1000 in TBS was then
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added and incubated for 2 hrs.

After washing, samples were

reacted with substrate (0.5mg/ml 4-chloro-l-naphthal + 5ml
methanol + 25ml 0.05M Tris pH 6.8 + 12ul 30% H202) .

The

reaction was stopped ater 20 min. by rinsing with distilled
water.

This process produced easily interpretable blots for

our BLV system.
All 24 serum samples (weeks 0 and 2-103) from one cow
were tested at the same time on nitrocellulose strips trans
ferred from one gel and all assays for each of the 12
experimental animals were conducted using the same reagents
and stock solutions.

To confirm relative locations of the

two major BLV proteins gp50 and p24 on each of the 12 sets
of nitrocellulose strips, a control strip was run using a
mixture of monoclonal antibodies against gp50 and p24 as
described (chapter 4).

Strips were also reacted with Con-A

to confirm the glycoprotein nature of certain proteins
(Clegg, 1982).
Strips were analyzed on a Chromoscan 3 Densitometer
(Joyce Loebel, England) and evaluated using the associated
Joyce Loebel computer assisted analysis program.

Linear

scans were plotted, valley to valley background corrected,
and peaks spotted to produce a corrected linear scan.
Figure 1 shows a corrected linear scan for week 12 PI of cow
149, who recognized all the BLV structural proteins.

Due to

the overlap of peaks resulting from reactivity to both a
wide band at gp50 and a 70kd protein, integral values
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Figure 1. After isonunoblotting, nitrocellulose 6trips were
read using a Joyce Loebel Chromoscan 3 Densitometer. Linear
scans were plotted, valley to valley background corrected,
and peaks spotted to produce a corrected linear scan. BLV
proteins identified are labeled.
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representing the total area under a curve could not be
calculated.

Maximum peak heights were therefore used to

evaluate antibody responses.
Results
Of the three diagnostic tests used, serum antibody res
ponses to BLV were detected earliest by the Western
procedure, followed by ELISA and finally AGID.

In several

instances, a positive test, indicating production of
antibody against BLV, was followed by a negative test using
AGID and ELISA, but not using the Western immunoassay (Table
1)

•

AGID results (Table 2), recorded as very weak positive
(+), weak positive (++) or positive (+++), indicated sero
conversion occurred at 3 weeks post infection in 3 cows, 4
weeks PI in 3 cows, 5 weeks PI in 2 cows and one cow seroconverted during each of weeks 7, 8, 9 and 11.

In six of

these cows, 86, 93, 94, 123, 131 and 132, identification of
antibody to BLV was followed by a negative tast.

Four of

these, 86, 93, 94 and 123 were negative for only one week,
while two cows, 131 and 132 were each negative for 5
tests/weeks after having been positive at weeks 4 and 5 PI.
In all but cow 86, these reversions occurred during the
first 10 weeks PI.

Although cow 86 had a strong positive

response by week 5 PI her antibody response became progres
sively weaker, was negative by week 59, but a very weak
positive thereafter.
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Table 1.

Cow #
76
86
93
94
99
122
123
131
132
140
144
149

Comparison of sero-conversion times detected
by AGID, ELISA and Western blot analysis.

AGID
51
5
4
3
11
3
8*
4*
4*
7
9
3

ELISA

Western
Blot

4
3
2
3
3
3
3
3*
3
3
3
3

3
2
2
2
2
2
2
2
2
2
2
2

1Weeks post infection.
*These samples were positive but subsequent samples were
negative for a period of time before again becoming posi
tive. See appendix or text for individual results.
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Table 2.

Results of Agar Gel Immunodiffusion Test

Wk

Cow numbers
■

76
0
1
2
3
4
5
6
7
8
9
10
11
12
16
20
25
34
43
51
59
68
77
85
94
103

VWk
wk
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

86

wk
wk
wk
+
wk
wk
wk
wk
wk
vwk
vwk
vwk
vwk
vwk
vwk
vwk
vwk
vwk
wk

93

wk
wk
wk
vwk
vwk
vwk
vwk
vwk
+
+
+
+
+
+
+
+
+
+
+
+

94

99

122

wk
wk
+
+
+
+
+
+
+
+
+
+
+
+

wk
wk
wk
wk
wk
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

wk
wk
wk
vwk
vwk
vwk
vwk
vwk
vwk
wk
vwk
vwk
wk
wk
wk
wk
wk
wk
wk
wk
wk

123

131

132

vwk
vwk

vwk
vwk

140

vwk
vwk
wk
+
+
+
+
wk
+
+
+
+
+
+
+
+

vwk
vwk
+
+
wk
+
+
+
wk
wk
+
+
+
+

vwk
vwk
wk
+
+
+
wk
wk
wk
+
+
wk
+
+

.

wk
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

144

149

vwk
vwk
vwk
vwk
+
+
vwk
+
wk
wk
+
+
+
+
+
+

+
wk
wk
+
+
+
wk
wk
wk
wk
wk
wk
wk
wk
wk
wk
wk
+
+
wk
+
+

ELISA results were more sensitive and more likely to
identify an antibody positive cow.

In general, cows were

grouped as high, intermediate or low responders based on
their reactivities to BLV at a 1:100 serum dilution over the
103 week experimental period (Figure 2, panels A, C and E).
Although the majority of the cows produced increasing
amounts of antibodies over time using ELISA assays, there
was no relationship between BLV antibody reactivity
demonstrated by ELISA and intensity of response or number of
proteins identified on Western immunoblots (Table 3).
Antibody responses measured by Western blot procedures
demonstrated a wide range of reactivities to the different
BLV proteins, but unlike the ELISA or AGID results, no low
or borderline responses were obtained that would lead one to
mis-diagnose the BLV infected status of the 12 experimental
animals.

The Western immunoblot demonstrated reactivity

with bovine serum to five structural proteins, gp50, gp30,
p24, pl5, pl2 and plO; two proteins of 70 and 45kd and
glycoprotein dimers of 162 and 85kd.

Evolution of antibody

titers to the viral proteins varied widely between and
within animals over time.

Some animals had similar antibody

responses to all the major viral proteins (Cow 99, Figure
3), while others had directly opposing responses even to
proteins which are produced from the same polyprotein
precursors (Cow 94 gp50 & gp30, Figure 4).

Antibody rose

slowly in some (Cow 93, Figure 5) and quickly in others (Cow

Reactivity of Serum on ELISA versus
Reactivity to gp50 using Western Immunoassay.

Figure 2. Elisa data is shown in panels A, C and E.
Western data of reactivity to gp50 is shown in panels B,
and F. Cows are grouped into high (A & B), intermediate
& D), and Low (E & F) responders based on their ELISA
results. Each group (A & B, C & D, E & F) contains four
cows, 2 AL and 2 PL.
-------,
- AL -...
,
- PL

!
4

200
175

3

150
125

100

2

75
1

50

0

4

200
175

3

150

Peak

125

100

2

75
1

Height

A bso rb ance

25

0

50
25

0

0

4

200
175
3

150
125

2

100
75

1

50
25

0
0

25

50

75

100 0

25

50

75

100

0

Weeks P ost In fe c tio n

U1
H
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Table 3.

Reactivity to BLV Proteins as detected by
Western Immunoassay
ENV

Cow #

GAG
p24

pl5

pl2

plO

22
20
22
23

17
23
23
22

16
15
5
13

14
15
5
13

15
14
7

20
18
21
20

22
22
22
22

23
23
23
23

12
1
1
12

7
9
11
16

19
22
23
20

19
22
23
22

23
23
23
23

gp50

gpso

Low1
94-AL
149-AL
131-PL
132-PL

22
22
20
20

Inter
86-AL
144-AL
122-PL
140-PL
High
76-AL
99-AL
93-PL
123-PL

-

1
-

5

-

-

9

14
8
13
8

'Low, Inter and High are the Low, Intermediate and High
groups assigned according to results of the ELISA assay
Each group of four cows has 2 AL and 2 PL animals.
2The total number of times this protein was observed on
Western blots over the 103 week experimental period. A
total of 24 serum samples were run for each animal.
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Figure 3. Western Immunoassay was run as described in text. The major BLV proteins
are labeled. Cow 99 had similar antibody reactivity to all three major viral
structural proteins, p24, gp30 and gp50.

Western Immunoblot of Cow 94
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Figure 4. Western Immunoassay was run as described in text. The major BLV proteins
are labeled. Cow 94 had an increased response to gp30 early PI, but lost this
reactivity later. In contrast, reactivity to gp50 was low early PI but increased
late PI.

Western Immunoblot of Cow 93
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Figure 5. Western Immunoassay was run as described in text. The major BLV proteins
are labeled. Cow 93 took several weeks to develop a strong antibody response to the
BLV structural proteins.

86, Figure 6).

Once elevated,

the antibody response to a

particular protein remained stable

in some animals (cow 140

gp50, Figure 7), regressed slightly (Cow 140 gp30, Figure 7)
or disappeared completely (Cow 86 gp30, Figure 6).

In the

majority of the animals, response to gp50 increased over
time, but response to gp30 and

p24 was more variable

(Figures 3-7, Cows 86, 93, 94,

99, 140).

Reactivity to p24

showed an early peak PI in most cattle in the AL stage of
disease progression, but in PL animals p24 generally
increased after conversion to the PL stage.

Antibody to the

smaller gag proteins, pl5, pl2 and plO was observed in the
majority of the cows, however, this reactivity was observed
primarily during the first 12-16 weeks PI and tended to
diminish thereafter (Table 4).
Reactivity of glycoproteins with Con-A was apparent
with gpl62, gp85 and gp50.

Although gp30 produced a wide

band on Western immunoassay as did the other glycoproteins,
it failed to react with Con-A (Data not shown).
Discussion
The accurate diagnosis of animals with low level antibody
response to BLV has been a problem in many serologic
studies.

Various assays have been used to increase the

sensitivity of antibody detection over the standard AGID
test, but these require the use of specialized reagents
including radiolabelled antigen for RIA (Deshayes et al.,
1977) or a source of specific anti-gp50 monoclonal
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Figure 6. Western Immunoassay was run as described in text. The major BLV proteins
are labeled. Cow 86 developed a strong antibody response to the BLV structural
proteins very quickly, but this response decreased after about 5 months, with
reactivity to gp30 disappearing completely.
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Figure 7. Western Immunoassay was run as described in text. The major BLV proteins
are labeled. Cow 140 had a strong response to gp50 which remained high throughout
the experimental period. However, the response to gp30 and p24 decreased with time
PI.
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Table 4.

Antibody Reactivity to the Small Gag Proteins

1
I 9
(12)

pl5
II
(6)

III
(6)

plO
II
(6)

I
(12)

pl2
II
(6)

III
(6)

103
7
11
5
7
9

4
2
3
2
6

—
1
—

—
9

10
8
7
3
8
10

2
1
1
2
5
5

1
2
1

—

—

—

4
9
5
9

4
2

1
-

I
(12)

III
(6)

AL
76
86
94
99
144
149

—

—

—

10
8
1
6

2
6
1
4

2
5

—
1
3
3
8
10

—
1
2
5
2

—
1
-

—

—

5

1

PL
93
122
123
131
132
140

1I, II and III represent time periods post infection. I =
weeks 1-12, II = weeks 16-51 and III = weeks 59-103.
2Total number of samples run during the time periods
indicated.
3The total number of positive samples showing reactivity
with a particular protein during the time period given.
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antibodies for the gp50 antigen capture ELISA (Portetelle et
al., 1983; Mammerickx et al., 1984).

Both assays must also

contend with a high level of non-specific background binding
commonly found when dealing with bovine serum.

We have

developed a Western immunoassay which can resolve all of the
BLV structural proteins including the 50 and 30Kd envelope
glycoproteins.

This assay was used to follow the serum

antibody response over time of cattle experimentally
infected with BLV and was compared to antibody detection by
AGID and ELISA assays.
A non-denaturing Western system was choosen to preserve
the important conformational epitopes of gp50.

The immune

response of BLV infected cattle to gp50 is primarily
directed against the CHO and conformationally dependent F, G
and H epitopes which are destroyed by SDS and heating (Burny
et al., 1985b).

Our nondenaturing system allowed us to

detect bovine antisera binding to wide bands of both gp50
and gp30 as well as two larger viral glycoprotein dimers of
162 and 85kd in the majority of samples tested.

The latter

two proteins are probably due to the non-denaturing system
used resulting in single (85kd) or double (162kd) gp50/gp30
dimers as reported by Mussgay et al. (1980).

The

glycoprotein nature of the larger molecular weight proteins
was confirmed by reactivity with Con A, though gp30 was not
detected.

Similar results have been reported by Deshayes et

al. (1977), using the periodic acid-Schiff stain and is
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probably due to the low carbohydrate content of gp30.
Non-specific background staining was eliminated in most
cows by the careful screening of all reagents used.

Both

serum and peroxidase conjugated second antibody were tested
at various dilutions to determine that combination which
allowed the detection of all BLV proteins with the minimum
of background from both high and low antibody responders (as
determined previously by ELISA reactivity to whole BLV).
Serial dilutions of serum from 1:80 to 1:1,280 and
peroxidase conjugated second antibody of 1:500 to 1:4000
were tested.

Alkaline Phosphatase conjugated second

antibody (Blake et al., 1984), was also tested as an
alternative to peroxidase but was found to increase
background non-specific binding without a proportionate
increase in specific reactivities for this system.
Background was also controlled by use of a blocking
agent both before and during antibody application.

Of all

blocking agents tested, the BLOTTO-like skim milk solution
from Bio Rad proved most effective.

The one factor that

contributed most toward the reduction of background non
specific binding was the three 5 minute 1M NaCl washes.
improvement over washes using PBS was dramatic.

The

After final

reagent specifications were established, the clarity of
antibody reactivity with the various protein bands was
further increased by decreasing the amount of antigen run on
each gel.

As a result of these modifications, the Western
immunoblot assay was the most sensitive serodiagnostic test
used in this study.

Antibodies against p24 were detectable

in all but one animal by 2 weeks PI and this animal reacted
by 3 weeks PI.

ELISA reactivity followed closely with a

positive test in all cattle by 4 weeks PI.

The AGID test

did detect seroconversion by 3 weeks PI in three cattle;
however, up to 11 weeks were needed to detect an adequate
antibody response in all cattle.

In both the ELISA and the

AGID test, the primary antigen is gp50, although small
amounts of p24 is present in the AGID and reactivity with
p24 is possible on the ELISA as evidenced by reactivity with
anti-p24 monoclonal antibodies (chapter 3).

Antibodies

against gp50 are usually the first to appear following BLV
infection followed closely by the appearance of anti-p24
antibodies (Miller and Van der Maaten 1975; Portetelle et
al., 1981; Cockerell et al., 1986; Djilali et al., 1987b)
however the detection of p24 before gp50 using RIA has also
been reported (Miller et al., 1981).
If one follows only the antibody reactivity to gp50 on
Westerns, the sensitivities of the assays change.

The ELISA

is most sensitive and AGID detected seroconversion one week
earlier or at the same time as the Western in 67% of the
animals tested.

The reason for the difference in gp50

reactivity could be explained by dilution factors or changes
in pertinent conformational epitopes of gp50.

Since F, G

and H are the primary epitopes of gp50 against which most
cattle develop an immune response and expression of these
epitopes is both carbohydrate and conformationally dependent
(Bruck et al., 1982b; 1984; Portetelle et al., 1989b), it
would follow that those assays which would denature gp50 the
least would be the most sensitive in detecting anti-gp50
antibodies.

In both the ELISA and AGID the primary antigen,

gp50, would be less denatured than in the native Western
procedure.

Although AGID is generally considered less

sensitive than other test procedures, its agreement with
Western gp50 results in this case may also be due to
differences in serum dilutions used in the various assays.
The AGID used undiluted serum, while both the ELISA and
Western used diluted serum.
The major advantage of the Western over the other two
diagnostic tests concerns the detection of cattle with low
level antibody responses.

False negative tests, resulting

from low antibody titers (Poli et al., 1981; Miller et al.,
1981; Todd et al., 1982) have been attributed to recent BLV
infections, the cow being close to parturition (Burridge et
al., 1982), or naturally occuring, consistently low antibody
titers (Kaaden et al., 1978).

In this study Western

immunoblots were consistently able to identify those animals
infected with BLV earlier post infection than either the
AGID or the ELISA assays.

Furthermore, no animals were

subsequently found negative using the Western after initial

seroconversion, as were one ELISA and 6 AGID tests.

The

apparent sensitivity and specificity of the Western
immunoassay lies in the ability to detect all viral
proteins.

Although high backgrounds did occur in a few

samples on the Western, an easily recognizable pattern of
BLV reactivity was readily identifiable above background.
In a cow with low antibody titers to gp50, reactivity to
other viral proteins on the Western can establish a positive
BLV response in this animal.

Cow 86, for example, was

negative by AGID week 59 PI but was positive to gp50, gp30,
p24 and pl2 on the Western immunoblot at this time.
Likewise, four cattle, with very low level reactivity to
whole virus on ELISA, two of which might have been
considered negative on ELISA if background values had been
much higher, showed a distinct pattern of reactivity to the
individual proteins on Western immunoassay leaving no
question of their BLV antibody status.
The difference between the responses demonstrated by
Western blot and the rather weak reactions shown by ELISA
for some cattle may have been due to the reagents used to
dilute the serum samples.

The ELISA diluent contained 0.1%

Triton X-100 while the serum diluent used for
immunodetection did not.

Recently, Merza et al. (1989),

reported that virus solubilized with 2% Triton X-100 did not
react as well in an ELISA with neutralizing monoclonal
antibodies directed against the F, G and H epitopes found on

gp50 as virus solubilized with Tween-20 or other non-ionic
detergents.

Since F, G and H are the primary epitopes

towards which most cattle develop an immune response (Bruck
et al., 1982b, 1984; Portetelle et al., 1989b), the use of a
small amount of this non-ionic detergent in the serum
diluent may have interferred with the ELISA.

It was not

stated if the detergent affected antibody binding via
conformational alteration of the pertinent epitope or via
some other mechanism of interference.

It is evident that

both the testing system used and the reagents involved in
that system can make a big difference in the outcome of a
particular diagnostic assay.
While the Western assay may take more time to run than
either the AGID or the ELISA, its lack of dependency on
detection of antibody solely to one BLV protein and its
ability to detect animals carrying very low titers of antiBLV antibodies clearly outweigh this disadvantage.

Early

detection of BLV infected cattle is a must in purebred herds
in which overseas shipment of cattle, or embryos, to regions
presently free of BLV is illegal if products originated from
BLV infected herds (Thurmond and Burridge, 1982).
The proposed use of gp50 as a vaccine (Ohishi et al.,
1988; Merza et al., 1989), will necessitate the development
of diagnostic assays that do not depend on the detection of
gp50.

The Western would be ideal in vaccination cases, as

reactivity against gp5Q alone could readily be distinguished

from a naturally infected cow responding to various BLV
proteins.

The Western immunoassay can result in a very

quick and effective diagnostic method for the detection of
BLV infection.

Chapter III
Clinical and Humoral Evaluations in BLV Infected Cattle
to BLV Structural Proteins
Introduction

BLV is a type C exogenous retrovirus which induces
three clinical manifestations in infected cattle:

an

aleukemic stage, a persistent lymphocytotic stage and a
lymphosarcomatous stage.

Thirty to seventy percent of BLV

infected cattle develop persistent lymphocytosis, in which
high lymphocyte counts may stabilize for long periods,
increase further or suddenly disappear with a return to
normal (Burny et al., 1985a, 1987b).

Less than 5% of

infected cattle develop the lymphosarcomatous stage which
occurs primarily in older animals (Marshak and Abt, 1967).
Although expression of BLV in vivo appears to be
suppressed at the level of transcription (Ferrer et al.,
1980; Portetelle et al., 1981; Notzell et al., 1982;
Kettmann et al., 1982, 1985; Burny et al., 1985a), some
level of protein expression must occur as many studies have
demonstrated a steady rise in antibody titer with disease
progression (Ferrer et al., 1974; Bex et al., 1979; Kono et
al., 1981; McGuire et al., 1981; Portetelle et al., 1981;
Mammerickx et al., 1980; Kaaden et al., 1978; Burridge et
al., 1982).
Although the mechanism of disease progression has not
as yet been elucidated, serologic surveys have been
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conducted to analyze the relationship of the humoral immune
response to BLV structural proteins and disease state.

High

antibody titers to the major gag protein, p24, of BLV have
been associated with malignant lymphoma in cows that also
have antibodies to the envelope glycoprotein, gp50 (Kono et
al., 1981; McGuire et al., 1981; Thurmond et al., 1985),
although others have demonstrated reactivity to p24 and
other BLV structural proteins in non-LS cattle (Mussgay et
al., 1980; Burny et al., 1980; Deshayes et al., 1980; Heeny
et al., 1988).

Most studies examined only the immune res

ponse to the two most easily obtainable and major BLV struc
tural proteins, gp50 and p24, however, Deshayes et al.
(1980) and Heeny et al. (1988) looked at immune responses to
all BLV structural proteins.

Their similar results

demonstrated that all sero-positive cattle reacted with gp50
and p24, but LS cattle were more likely to possess
antibodies that react with gp30, plO, pl2 and pl5, than sera
from clinically "normal" cattle.

Deshayes et al. (1980) at

tributed these findings to possible quantitative differences
in exposure to antigen.

The increase in lymphocytes

containing an integrated BLV genome ranged from 5% in AL
cattle, 25-40% in PL cattle, and in the majority of the
cells in LS cattle, leads one to suspect these animals would
also have a corresponding increase in production of viral
proteins although this association has not been proven
(Kettmann et al., 1979, 1980a, 1980b, 1981).

While most

studies have found an increase in BLV antibody levels occur
in advanced stages of the disease (Ferrer et al., 1974;
Portetelle et al., 1978, 1981; Bex et al., 1979; Kono et
al., 1981; Mammerickx et al., 1980; McGuire et al., 1981;
Thurmond et al., 1985; Heeny et al., 1988), the time these
increased titers begin and their relationship with disease
progression or length of time in a particular BLV disease
state has not been established.

Although many investigators

have examined the immune response of BLV infected cattle to
various viral proteins, few have correlated these results
with a planned prospective study of the clinical response to
the disease.

Most investigators do not distinguish between

the first two clinically "normal" phases of disease progres
sion (AL and PL), or to the length of time an animal had
been in this state when samples were taken.
In this study, clinical data was correlated with humor
al immune responses to BLV proteins following a planned
infection.

Three novel clinical manifestations were noted

to occur transiently during the first 16 weeks post
infection: lymphocytosis, eosinophilia and lymph node
enlargement.

Additionally, antibody titer to the envelope

protein, gp50, increased with time PI regardless of disease
state.

By contrast, antibodies against other viral

proteins, pl5, pl2 and plO tended to increase early post
infection and diminish with time PI.

The most notable

difference between AL and PL cattle was in their reactivity
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towards the gag protein, p24.

The majority of the AL cattle

developed a strong antibody response to p24 within the first
6 weeks post infection, while PL cattle tended to have lower
initial responses and developed increased responses to p24
only after converting to the PL state.
Materials and Methods
Animals and Blood Samples
Twelve holstein heifers, 12-18 months of age, were ac
quired from Wisconsin through the Louisiana School of Veter
inary Medicine.

Prior to entering this study all heifers

tested negative for exposure to bovine syncytial virus
(BSV), bovine immunodeficiency virus (BIV), anaplasmosis and
brucellosis.

In at least four separate blood samples taken

over a nine month period, hemograms were normal and cows
were antibody negative for BLV using the agar gel
immunodiffusion (AGID) test (Leukassay-B, Pittman-Moore
Inc., Washington Crossing, NJ).

Cows were maintained on a

routine vaccination (IBR, BVD, PI3) and de-worming schedule
during the course of the experiment and at no time were
elevated parasite burdens found in any of the heifers.
The source of the inoculum, an aged holstein donor in
the PL stage of BLV disease, was a member of the LSU
teaching herd and as such was on a regular de-worming and
vaccination schedule (IBR, BVD, PI3) .

She was screened and

found negative for evidence of recent exposure to
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brucellosis and anaplasmosis using the respective card
agglutination tests and for leptospirosis using the standard
agglutination/lysis test.

Antibody titers of less than 1:10

were detected using an indirect immunofluorescence assay for
IBR, BVD, PI3, and chlamydia, and a negative test for Johnes
and Blue Tongue was run using AGID.

Antibody reactivity to

BLV was confirmed using the standard AGID test.

No

significant antibody response to BSV or BIV was detected by
ELISA from two separate serum samples taken two weeks prior
to and one month following her use as a BLV donor.

One

milliliter (19.6 x 106 PBL) of whole blood was used to
inoculate each cow IV.

This same animal was used in similar

studies in which as little as 0.1ml of her blood transmitted
BLV to recipient calves (Foil et al., 1989).

Prior to, and

following inoculation, cows were pastured in an area
isolated from other cattle until all animals sero-converted
as detected by AGID.

Ethylenediamine-tetraacetate (EDTA)

treated blood for CBCs and preservative free blood for serum
samples were taken at the following intervals:

once a week

for three months, once a month for three months, and once
every two months for 18 months.

Physical and/or visual

exams were conducted at these time points to check for signs
of lymphadenopathy.

At the termination of this study, cows

were examined rectally for the presence of enlarged lymph
nodes that may not have been otherwise detected.
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Hematological Examination.

The number of leukocytes per microliter of whole blood
were determined using an automated cell counter (Coulter
model 5790).

Differentials were obtained by counting 100

leukocytes on blood smears stained with a Wright-Giemsabased stain.

Hematological classifications were based on

standard criteria described by Kenyon and Piper (1977a)
which considers an animal to be PL if it has an absolute
lymphocyte count for three consecutive monthly bleedings
that were greater than 2.5 standard deviations above the
normal mean established for that animal's breed and age
group (Kenyon and Piper, 1977a).

To more accurately assess

the lymphocyte counts above which an animal was considered
PL, the established mean was not used, instead, the average
of four absolute lymphocyte counts taken from each of the 12
animals over an 8 month period prior to BLV inoculation were
used as normal reference counts.

This method was decided

upon due to the wide variation from the mean of normal
lymphocyte counts found between our 12 heifers prior to BLV
inoculation.

Table 5 shows the average lymphocyte count and

standard deviation (SD) obtained for each cow.

The counts

above which an animal was classified as PL are shown in the
last column of Table 5 (Lymph Avg + [2.5 x SD]).

Similarly,

eosinophil counts were considered elevated if they were
greater than 2.5 x SD for the eosinophil average obtained
for each cow during the 8 month pre-inoculation interval.

73

Table 5.
Cow #

76
86

93
94
99
122

123
131
132
140
144
149

Pre-infection lymphocyte counts

Lymphocyte
Average
7.3
7.2
6.1
6.1
4.6
4.5
4.8
4.3
4.0
6.5
5.5
4.5

Standard
Deviation
.88
.75
.75
.67
.39
.68
1.58
.76
.71
.53
1.17
.68

Lymph Avg
+2.5 x SD
9.5
9.1
7.5
7.8
5.6
6.2
8.8
6.3
5.8
7.8
8.4
6.2
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Antigen Preparation

Fetal Lamb Kidney cells (FLK) were obtained from a lamb
taken by cesarean section at 142 days gestation.

Monolayer

cell cultures were established using the enzymatic
disaggregation method as described by Freshney (1983).
cells persistently infected with BLV (FLK-BLV)

FLK

(Van der

Maaten and Miller 1975a) were obtained from Dr. Van der
Maaten (NADC, Ames IA).

Monolayer cultures of each cell

line were grown in 750 cm2 roller bottles and maintained in
MEM containing 25mM HEPES, 10% fetal calf serum and anti
biotics (100 IU penicillin/ml and 100 ug streptomycin/ml).
Culture fluids were harvested every other day and stored at
4 °C for a maximum of 48 hours.

Supernates (180 ml volumes)

were clarified at 4°C by centrifugation at 13,000 x g for 15
min in a Sorval GSA rotor.

Supernates, containing either

virus or cell membrane fragments from the FLK-BLV and FLK
samples respectively, were pelletted by overlaying a ten
milliliter cushion of 20% glycerol with 190 mis of clarified
media and centrifuging at 53,000 x g for two hours at 4°C in
a Beckman SW19 rotor.

Pellets were resuspended in 1-2 mis

of phosphate buffered saline (PBS).

The uninfected FLK

preparation contained no known viral particles as detected
by IFA using antisera to IBR, BVD, BT, PI-3, BRSV, BCorV,
BRotaV, BPV, BHM, BH-3, PrV, Pseudo cowpox, CE, and
Chlamydia psittaci.

Protein concentration was determined

using the Bio Rad microplate system (Bio Rad Laboratories,
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Richmond, CA.).

Samples were frozen at -70°C in 2ral ali

quots until needed.

Solutions (100X) of BLV positive or

negative antigen were made in PBS, aliquoted into 500 ul
amounts and stored at -25°C until used in the ELISA assays.
AGID/ ELISA and Western Assays for the Presence
of BLV Antibody Reactivity
Serum antibody responses were evaluated using three
detection methods.

The AGID was used primarily to indicate

infection of the experimentally infected cattle.

The

progression of antibody response over time was evaluated
using the ELISA and Western immunoassays.

The ELISA assay

was used to asses the antibody response to the partially
purified virus, while Westerns gave us the immune response
to individual viral proteins.
Serum samples were tested for precipitating antibodies
to commercially prepared BLV glycoproteins using the stan
dard AGID test.

This antigen preparation contains BLV-gp50

and a small amount of p24 (Pittman-Moore Inc., Washington
Crossing, NJ).

Test plates were incubated in a humidified

chamber for 48 hrs before reading (Committee on Bovine
Leukemia Virus, 1980) .
ELISA assays were run using modifications of the
procedure described by Todd et al. (1980, 1982).

Briefly,

antigen (lOOng/well in .06M sodium bicarbonate buffer pH9.6)
was added to 96-well Immulon (Dynatech Lab. Inc. Chantilly,
VA.) microtitre plates and allowed to adsorb overnight at

room temperature.

Nonbound antigen was removed and the

plates were washed with one molar NaCl solution containing
0.05% Tween 20 (wash solution).

Plates were blocked for 1

1/2 hrs with 150ul/well of 10% goat serum in PBS.

Cow sera

were diluted in serum diluent (PBS with 1M NaCl and 0.1%
Triton X-100) at 1:50, 1:100 and 1:200, and added to the
antigen-coated test plates.

Sera were incubated at room

temperature for 1 hr and removed by three five minute washes
using the wash solution.

Peroxidase conjugated goat anti-

bovine IgG (H&L) (Pel-Freez, Rogers, AK) diluted 1:1000 in
serum diluent was added, 45ul/well, and allowed to incubate
30 minutes at room temperature.
lOOul of enzyme substrate,

Plates were washed, and

(0.05M citrate buffer, pH4.0 +

l.Omg/ml Ortho-phenylenediamine dihydrochloride [Sigma, St.
Louis, MO.] + 0.5ul/ml of 30% H202) was added and incubated
for 20 minutes.

The reaction was stopped by the addition of

50ul/well of 2.5M sulfuric acid.

Plates were read on a

Dynatech micro-ELISA reader at 495nm wavelength.

All

samples for individual cows were run on the same day using
the same reagents and time intervals. Samples with high
antibody levels and corresponding absorbance values over the
maximum level which could be reliably detected by the ELISA
reader were read after a 1:3 dilution with a mixture of one
part 0.05M citrate buffer, pH4.0 and two parts 2.5M sulfuric
acid.

The resulting absorbance values were multiplied by 3

to obtain an adjusted absorbance value (Newman et al., 1988;
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Newman, personal communication).
Each serum sample was tested in triplicate using both
FLK and FLK-BLV antigen preparations.

Multiple dilutions

were used as titration data give more reliable measures of
antibody quantity than absorbance values of single point
assays.

Control wells without serum (conjugate control) or

without serum and peroxidase conjugated antibody (antigen
control) were included on each plate.

To correct for

background caused by non-specific serum binding, the ELISA
test results were calculated in a two step process
incorporating methods reported by both Todd et al. (1982)
and Florent et al. (1988).

First, the absorbance value ob

tained for the conjugate control wells on either FLK or FLKBLV antigen was subtracted from the corresponding absorbance
values obtained using the bovine serum.

Secondly, the

corrected value for serum on FLK antigen was subtracted from
the corrected value for serum on FLK-BLV antigen to give a
final absorbance value for reactivity to BLV for each sample
(Figure 8).

In addition to running triplicate

samples/plate, the majority of the sera were retested at
least once to confirm the validity of absorbance values
obtained.
Western Blots of BLV proteins and immunodetection with
bovine serum were run under conditions previously described
(Chapter 2).

The same crude BLV extract used for ELISA was

separated using 12% PAGE under non-denaturing conditions,
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Correction of Absorbance Values for ELISA Data
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Figure 8. This figure demonstrates ELISA values obtained
after correction for background non-specific binding has
been made. (Absorbance values obtained for the conjugate
control wells on either FLK or FLK-BLV antigen was subtract
ed from the corresponding absorbance values obtained using
the bovine serum.) The adjusted values for reactivity
against FLK as antigen is shown by open circles and against
FLK-BLV by the closed circles. The standard deviations for
each sample are indicated.

transferred to nitrocellulose paper and allowed to react
with the serum. All 24 samples (weeks 0 and 2-103) from one
cow were run at the same time on nitrocellulose strips
transferred from one gel using the same reagents and stock
solutions.

In addition to the use of molecular weight

standards, (Sigma, St. Louis, Mo.) monoclonal antibodies
reactive against p24 and gp51 were used as controls to
affirm relative positions of antigen on the nitrocellulose
strips with each set of serum samples run.

Strips were also

reacted with Con-A to confirm the glycoprotein nature of
certain proteins (Clegg, 1982).
The density of color was used to estimate the amount of
antibody reactivity of each sample and was analyzed using a
Chromoscan 3 Densitometer (Joyce Loebel, England).

This

data was evaluated using the associated Joyce Loebel
computer assisted analysis program.

Linear scans were

plotted, valley to valley background corrected, and peaks
spotted to produce a corrected linear scan.

A corrected

linear scan for week 12 PI of cow 149, who recognized all
the BLV structural proteins is shown in chapter 2, Figure 1.
Due to the overlap of peaks resulting from reactivity to
both the putative pre70ga9 and gp50, integral values
representing the total area under a curve could not be
calculated accurately and therefore maximum peak heights
were used to evaluate antibody responses.

Results
Clinical Signs

At the conclusion of this study, 103 weeks PI, 6 AL and
6 PL cows were identified.

Figures 9 - 2 0

(found in the

Appendix) demonstrate the total WBC and absolute lymphocyte
counts for each cow over the entire course of this study.
Of the 6 cows entering the PL stage, two became PL at 2
weeks PI, two at 11 weeks, one at 51 and one at 68 weeks.
Total lymphocyte counts were very variable between PL
cattle, and within some animals over time, however, once
diagnosed as being in the PL state, none reverted to the AL
state (Table 6).
Three novel clinical observations were made during this
study:

transient lymph node enlargement, transient lympho

cytosis and transient eosinophilia (Table 7).

All three of

these symptoms occurred briefly during the first five months
PI in several cows.

Moderate lymph or hemal lymph node

enlargement of the pre-femoral, pre-scapular and cervical
areas was observed between 8 and 12 weeks PI in half of the
BLV infected cattle.

Of the 6 cows showing this

enlargement, 5 were AL and 1 was PL.

Transient lymphocy

tosis occurred 2-16 weeks PI in nine animals, five of which
were AL and four were PL.

The maximum cell counts observed

were not different between the AL and PL groups.

Transient

eosinophilia was observed in 9 cattle from both the AL and
PL stages of disease progression.

The majority of the
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Table 6.
Cow #

93
140
122
131
123
132

PL Status of BLV Infected Cattle

week
converted
11
11
2
2
51
68

PBL
count1
High
High
inter
inter
inter
low

fluctuation2
no
yes
no
yes
no
no

1Hiqh = average count > 24 x 103/ul, Intermediate > 13 x
10 /ul and low > 9 x 103/ul
fluctuation = changes in cell counts occuring after week
12 PI once the PL state has been reached.
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Table 7.

Kinetics of Transient Symptoms
during First 5 Months PI.
Weeks Post Infection

Ultimate
Status
AL

Cow #
76
86
94
99
144
149

Eosin.1

Node Increase2

TL3

4
20
7 - 8

12
10 - 11
11

3 - 5

—

7 - 12
9 - 16
7
20
—

8-12
10 - 12

4
2
3
2

-

16
12
7
7

PL

93
122
123
131
132
140

4 - 20
5 - 16
5 - 9
6 - 12

2 - 8
3 - 8
11 - 12

2 - 11
3 - 8

1Eosin. - Eosinophilia
increase in size of either lymph or hemal lymph nodes.
3TL - Transient Lymphocytosis
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eosinophil increases occurred between weeks 4 - 20 PI,
however, eosinophilia was not consistently detected during
this time (Table 8, in appendix).

Four cows had increased

eosinophil counts at least once after the 20th week PI.
Serum Antibody Responses
ELISA Data and Clinical Signs
The development of antibodies to BLV over time in our
experimentally infected cattle was initially evaluated using
an ELISA assay system.

Cows were grouped as high,

intermediate or low responders based on their pattern of
antibody reactivity (at 1:100 serum dilution) during the 103
week test period.

Each of these groups contained an equal

number of AL and PL animals (Figure 2, panels A, C & E).

No

apparent differences were observed between the antibody
reactivities of AL and PL cattle, and the majority of the
heifers demonstrated an increase in ELISA titer over time
regardless of clinical status.

Therefore, we looked to see

if this increase in ELISA titer corresponded to increased
reactivity to specific proteins using a Western immunoassay.
Western Antibody Response and Disease Progression
Antibody responses measured by Western immunoassay
demonstrated a wide range of reactivities to the different
BLV proteins (Figures 3-7 and 21-27 in Appendix).

The

strongest reactions demonstrated by all cattle were against
the envelope and core proteins gp50 and p24 respectively.
However, moderate reactivity was also observed by all
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animals throughout the study against the envelope protein
gp30.

Less consistent responses were also observed against

proteins with molecular weights of 162, 85, 70, 15, 12 and
10 kd.

Eight cattle also reacted to several proteins

between 50 and 24 kd during the first 3-6 weeks PI.
Reactivity to the smaller gag proteins, pl5, pl2 and
plO is given in Table 4.

The main difference between AL and

PL animals was in the response to plO.

While neither group

of heifers reacted with plO as often as with pl5 or pl2,
more PL heifers showed reactivity to it and reacted over a
longer period of time than did the AL group.

In both AL and

PL animals, reactivity against these smaller gag proteins
was most commonly found in the first three months PI and
diminished with time.
The overall pattern of antibody response to the major
structural proteins, gp50, gp30 and p24, was very different
between and within cows (Figures 28-30).

Antibody

reactivity against gp50 tended to increase over time
regardless of disease state; however, the response to gp30
and p24 was more variable.

The most striking difference

between AL and PL cows was found in their reactivity to p24
(Figure 31).

AL cattle tended to have a rapid increase in

antibody response to p24 occur within the first 12 weeks PI
followed by decreasing antibody titers, while PL cattle were
less likely to have an initial strong peak but increased in
their p24 reactivity after entering the PL state.

However,

Antibody Response Detected by Western Immunoassay

Figures 28-30. Western immunoblots for each cow were
scanned, peak heights measured and plotted over time PI
for p24, gp30 and gp50.
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and plotted
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The peak heights obtained on Western immunoassay for p24 were averaged
over time.
average of 5 AL cows.
average of 4 PL cows which entered the PL state between 2 and 11 weeks
PI.
........ - average of 2 PL cows which entered the PL state 51 and 68 weeks PI.
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the two PL cattle which entered the PL state late PI had a
pattern of antibody reactivity that resembled the AL cattle
early PI and the PL cattle late PI.
Discussion
Clinical Data
The mechanism of disease progression following
infection by BLV has not as yet been elucidated.

In an

attempt to define the role of humoral immune responses in
the pathogenesis of the different BLV disease states, we
experimentally infected 12 cattle and followed their humoral
immune responses and disease progression.

At the conclusion

of this study, half had reached the PL stage of BLV disease
progression, half remained AL and none had progressed into
the LS stage.

Of those that entered the PL stage, the times

of conversion varied from 2 to 68 weeks post infection.

The

total lymphocyte counts found in these animals was also very
variable over time in some animals, but remained fairly
constant in others.

The physiological mechanisms behind

these wide differences in time of disease induction and in
clinical signs of disease within the PL cattle have not as
yet been identified.
Clinically, three novel signs were observed to occur
transiently within the first 20 weeks PI:

eosinophilia,

lymphocytosis and a moderate increase in lymph or hemal
node size.

Although these transient signs were observed in

both AL and PL animals, the increase in lymph node size
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appeared predominantly in AL animals.
Transient eosinophilia is rarely mentioned in the
literature, but has been reported to occur after infection
with BLV.

Seil et al. (1963), and Nobel et al. (1965), con

firmed observations first made by Gotze (as reported in
Straub et al., 1987a) of the presence of a transient eosino
philia lasting less than 35 days in some BLV infected
animals.

This eosinophilia occurred prior to the lymphocyte

increase and had returned to normal by the time the cow was
recognized as leukotic (by one of the leukosis keys).
Eosinophilia was thus a pre-leukosis indicator.

In this

study, its appearance seemed to be more closely related to
time PI rather than to an impending change to the PL stage,
as transient eosinophilia was observed in 9 cattle in both
the AL and PL stages during the same general time interval
PI.

Cow 132 had a second episode of eosinophilia during

weeks 59 and 68, converting to the PL stage at 68 weeks PI.
Elevated eosinophil counts were observed intermittently over
the entire experimental period for one AL cow.

This animal

was the "poor doer" of the group and could possibly have had
a chronic respiratory infection that contributed to her
eosinophilia.

It appears unlikely that the elevated

eosinophil counts were a result of parasite infestations as
all cattle were maintained on a regular de-worming schedule
and checked for evidence of parasites routinely throughout
this study.

While most of the increased eosinophil counts
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occurred before week 20 PI, fecals run at 16 wks PI showed
no more than 3 EPG Trichostrongylus species in any animal
and only 3 EPG Fasciola hepatica in 2 animals.
The transient lymphocytosis which occurred within the
first three months PI has not been previously reported in
the literature.

However, Meiron et al. (1985), gives

representative counts for 2 of 16 calves they experimentally
infected with BLV.

Both of these animals show a substantial

increase in lymphocyte numbers 4-6 weeks PI.

Meiron et al.,

did not give lymphocyte numbers for the other 14 calves nor
did he mention a transient effect in his paper.

In this

study, transient lymphocytosis occurred in both AL and PL
animals and lymphocyte counts were similarly elevated in
both groups.

Of the three cattle not showing an initial

transient rise in lymphocyte counts, two converted to the PL
stage at 2 weeks PI maintaining high counts from week 2
throughout the study.

The other cow without an elevated

lymphocyte count early PI had the strongest humoral response
as measured by ELISA of any experimental animal during this
early time PI.
LaBelle and Conner (1964) observed enlarged hemal lymph
nodes along the cervical vertebrae or in the paralumbar
fossa of BLV infected cattle consistently in the early LS
stage of disease progression.

In this study, the majority

of the cows showing mild node enlargement were AL.

The only

PL animal to demonstrate this phenomenon was the last to
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convert to the PL stage at 68 weeks PI.

This suggests that

those animals with enlarged lymph nodes also developed some
kind of protective response inherent in disease control
early PI.
There is apparently some proliferative response induced
by BLV that causes this increase in node size and the number
of lymphocytes and eosinophils.

This response may be a

direct result of the BLV pX proteins or an indirect response
of host proteins working together with the BLV pX proteins.
The transient lymphocytosis and lymph node enlargement
observed early after BLV infection are very similar to signs
induced late in BLV disease progression.

This leads one to

suspect that the terminal stages of BLV infection are indeed
due to a lack of control of certain events precipitated by
BLV infection.

These same events would occur immediately

PI, inducing similar disease symptoms until such time as the
immune response or other factors such as Plasma Blocking
Factor (Gupta and Ferrer 1982; Gupta et al., 1984) can gain
control and limit disease progression.

Those animals which

developed the node enlargement early PI may have developed
the necessary immunity, be it humoral or cell mediated, to
prevent a similar episode from occurring later PI.

A

breakdown in this control could then induce disease
progression as was seen in cows 123 and 132 who converted to
the PL state at 51 and 68 weeks PI respectively.
The mechanism inducing these transient increases are

unknown, but induction by the pX regulatory proteins is
probable.

Derse (1988), using recombinant DNA techniques

and complementation studies demonstrated production of full
length mRNA (9Kb) encoding the gag, prt, and RT proteins and
singly spliced (5.1Kb) mRNA encoding env, require the ex
pression of the pX regulatory proteins p38 and pl8, but,
these proteins are not necessary for the production of their
own doubly spliced 2.1Kb mRNA.

Derse also demonstrated the

proviral LTR is apparently unable to synthesize enough pl8
or p38 to sustain self activation.

Thus, in vivo, immedi

ately after BLV infects a cell, virus transcription would
predominantly yield the double-spliced pX mRNA, resulting in
the subsequent low level accumulation of pl8 and p38.
Acting singly or in combination with host factors, these two
proteins could "trans" activate B-cells resulting in
increased lymphocyte production.

Burny et al. (1987b), has

suggested a similar mechanism for the increase of slgM on
BLV infected B-cells via p38 "trans" activation of the Ig
enhancer.

Meiron et al. (1985) and Trainin et al. (1981)

have shown that the total IgM level increased up to the
fifth week PI in BLV infected calves and stayed elevated
until around 8-16 weeks PI at which time their IgM levels
began to decrease.

Ferrer et al. (1979), demonstrated that

in short-term in vitro cultures of BLV infected lymphocytes,
a subpopulation of cells spontaneously incorporates
thymidine.

Because the activity of these cells could be

inhibited by sera containing BLV antibodies, he believed
these cells may be responsive to the presence of BLV anti
gens produced in the culture.

However, these cells may be

driven by the action of pX or similar proteins that are
inhibited by factors present in serum, such as PBF or antipX antibodies rather than antibody to structural proteins.
In vivo, when these BLV controlling factors accumulate in
serum, "trans" activation would be diminished, resulting in
the decreased stimulation of cells and a return to normal
activity.

The time interval seen for the resolution of

early transient symptoms such as lymphocytosis, node
enlargement and elevated serum IgM levels would seem to
correlate with the time necessary for the induction of serum
factors or BLV antibodies in these infected animals (5-16
weeks PI).

A decrease or modification of these same factors

may allow disease progression to occur.
Serological Data
The serological responses to BLV proteins were
monitored over time using AGID, ELISA and Western
immunoassays.

All BLV structural proteins were identified

in the majority of infected cattle at some point during this
two year study using a non-denaturing Western system.
Antibody titer as detected by ELISA tended to increase over
time in all animals.

These titers did not correlate with

disease state, nor did they always correlate with the
reactivities to individual proteins as demonstrated by
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Western immunoassays.

Antibody to p24 appeared first on

Western assays in most cattle and an immediate strong
response to p24 along with a corresponding increase in node
size was observed in the majority of the cattle that
remained in the AL stage.
Antibody reactivity over time was first analyzed using
the ELISA.
as antigen.

The ELISA assay used pelletted semipurified BLV
Although the exterior of the intact virus is

covered with gp50/gp30 dimers, the virus pellet must also
contain disrupted virions as both gp50 and p24 monoclonal
antibodies reacted in an ELISA using the same pelletted BLV
as an antigen source (Tables 9 & 10).

Reactivity of the p24

monoclonal antibody implies that the viral core is at least
partially exposed in this assay and thus the ELISA could
measure the overall immune response to all viral structural
proteins.

Although the cows fell neatly into three groups

(high, intermediate or low responders), based on their
antibody reactivity, no correlation of antibody response
with disease state could be made.

Most of the literature

implies that antibody titers increase with BLV disease
progression (Ferrer et al., 1974; Bex et al., 1979;
Mammerickx et al., 1980; Kono et al., 1981; McGuire et al.,
1981).

However, in this study, the PL cow with the highest

WBC count was in the intermediate antibody responding group
and a cow with one of the highest responses measured by
ELISA was AL throughout the study.

The majority of the cows
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did however, develop an increased antibody response over
time regardless of disease state.

This increase is

apparently a function of time PI.
Because no correlation between ELISA data and clinical
signs could be found, the Western assay was run to evaluate
the immune response to individual viral proteins.

The non

denaturing Western assay used in this study allowed the
detection of antibody binding to all BLV structural proteins
(Ghysdael et al., 1979; Mamoun et al., 1983a, 1983b).

The

glycoproteins tended to produce wide bands on the gels, with
gp50 falling between the 45-60kd range and gp30 between the
30-35kd range, while the gag proteins produced distinct
narrow bands.
Strong responses to the major structural proteins gp50
and p24, and moderate responses to gp30 were found in all
cattle tested throughout the study.

Weaker reactivities to

the smaller gag proteins, pl5, pl2 and plO, was evident in
most cattle at some point during the experimental period.
In addition, proteins of 162, 85, and 70kd were detected in
all cattle and a 45kd protein was detected in 10 heifers.
The presence of a 162kd protein containing 2 molecules of
gp50/30 dimers and an 85kd protein containing one gp50/30
dimer has been previously demonstrated on gels run under
similar non-denaturing conditions (Mussgay et al., 1980).
We confirmed the glycoprotein nature of these high molecular
weight proteins by reactivity with Con-A (data not shown).
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The 70 and 45 kd proteins are probably gag precursors
(Mamoun et al., 1983b; Yoshinaka et al., 1986).

Pre70989 has

been previously demonstrated in disrupted whole virus (Gupta
et al., 1980) and the 45kd protein reacted with our anti-p24
monoclonal antibodies (Chapter 4, Figure 36).

The lack of

reactivity of anti-p24 with the presumed pre70ga9 protein may
be due to a conformational masking of the reactive epitope
in the larger precursor protein which is subsequently
revealed in the 45kd protein.

Bovine serum generally

reacted to the 45 and 70kd proteins early PI, decreased with
time and did not correlate with disease state.
Antibody against gp50 was produced 3-10 weeks PI in all
cattle and either increased progressively or was maintained
at high levels in the majority of infected animals.

There

were only 2 AL animals which decreased in gp50 antibody
reactivity after reaching peaks at 8 and 59 weeks respec
tively.

Antibody response to gp30 was usually much lower

than reactivity to gp50, however reactivity to both proteins
followed the same general overall pattern in 6 cattle.

In

the other 6 cows, gp30 reactivity either remained stationary
or decreased as the anti-gp50 titer increased.

Neither gp30

or gp50 antibody responses, correlated with disease
progression, however, gp50 reac-tivity increased over time
PI regardless of disease progression.

This increasing gp50

antibody titer most closely correlated with similar patterns
observed using ELISA (Figure 10) .

Antibody reactivity to p24 showed different patterns in
AL versus PL cattle.

Cattle were divided into three groups

and their p24 antibody responses were averaged and plotted
over time (Figure 31).

The first group consisted of the 5

AL cattle which had similar patterns of reactivity to p24.
The PL cattle were divided into two groups, the first
contained the four cattle that entered the PL stage between
2 and 11 weeks PI, the second group was composed of the two
cows that converted to the PL state late PI (weeks 51 and
68).

In the AL group, a rapid and strong increase in p24

reactivity occurred within the first 12 weeks PI followed by
a steady decline in p24 reactivity.

In the first PL group,

the average p24 response showed a gradual and steady
increase over time PI.

In contrast, the two cattle that did

not enter the PL stage until 51 and 68 weeks PI had a split
response.

Their response resembled the reactivity of AL

cattle early PI, but, after entering the PL stage of disease
progression more closely resembled the other PL cattle.
This suggests that an initially high antibody response to
p24 may aid in the control of disease progression.

In

contrast, the increased titer observed after the PL state
occurs is probably a result of increased exposure to the
presence of this particular antigen.

An initially high

titer to p24 may act to sequester BLV in a certain cell type
or organ early PI which in turn may affect the ability to
induce disease progression thereafter.

This is supported in
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part by correlation with the clinical data concerning early
lymph node enlargement.

The five AL cattle which

demonstrated early node enlargement were also the same five
which had their highest reactivity to p24 early post
infection.

The only PL cow to show lymph node enlargement

(132) had a very strong response to p24 by 3 weeks PI.

This

was higher than any subsequent response made by this animal
until after she converted to the PL state at 68 weeks PI.
Of the smaller gag proteins identified on westerns, plO
was recognized by more PL than AL cattle during the first 12
weeks PI.

This tends to indicate that PL cattle may be

exposed to a wider range of viral proteins than are AL
cattle.

Reactions to p24 however, must also be considered.

In this study, the AL cattle recognized and had an increased
response to p24 earlier than did the PL cattle.

All the gag

proteins are supposed to be made from a common precursor, so
one would expect the immune response to the individual
proteins resulting from that precursor to develop similarly.
It is interesting that during the first 12 weeks PI, AL
cattle tended to have stronger reactions to p24 than PL
cattle but PL and AL animals had similar responses to the
smaller gag proteins.

This same selective process occurred

with envelope protein identification.

Although both gp30

and gp50 are produced from the same precursor protein, gp30
antibody was elevated at times when gp50 antibody was at
very low levels (cow 94, Figure 4).

Perhaps some mechanism
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of selective processing of these protein precursors occurs
that is different between cows.

The ability to present a

specific protein on the cell surface and subsequently
develop an appropriate immune response may well influence
disease progression in various animals.

Cell mediated

responses in the form of macrophage antigen presentation or
helper-T cells may also influence this differential antibody
response to the various viral proteins.
One must also consider the importance of the cell
mediated immune response in those cattle that have
efficiently controlled BLV disease progression.

It is

possible that a protective cell mediated response, with or
without the additional influence of humoral responses such
as that found against p24, could subsequently aid in the
control of expression of various viral antigens and limit
disease progression more efficiently.

Cells expressing a

particular antigen such as the pX proteins may be
selectively destroyed by antigen specific CTL's, while cells
expressing antigens to which a CTL response has not
developed would trigger the increase of the humoral immune
response to that antigen.

Thus, an increase in the humoral

immune response to proteins not necessarily involved in
disease progression may be found.

The MHC also plays a role

in the ability of cattle to respond to individual antigens
on a cellular basis and certain BoLa types have been
associated with specific disease states (Stear et al., 1987;
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Burny et al., 1980).

In light of this, BoLA typing was done

on these 12 animals, but did not correlate with disease
progression in this study (data not shown).
In summary, three novel clinical manifestations were
observed during the first four months PI: transient
lymphocytosis, eosinophilia and lymph node enlargement.
Transient lymph node enlargement and temporally associated
high antibody response to p24 was found in the majority of
AL heifers.

Some mechanism of early disease control is

suggested.

We have also shown that cows with high ELISA

absorbance values did not necessarily identify more proteins
on Western blots nor did they always have correspondingly
high peak values.

Similarly, antibody levels to all viral

structural proteins did not increase over time or with
disease progression in the first two "clinically normal"
disease states.

In fact, our data suggest that individual

cows mount differential immune responses over time to
proteins that are produced from the same polyprotein
precursor.

This suggests a mechanism of differential

antigen processing, antigen recognition or both.

These

differences in antibody response and their relationship with
disease progression must still be resolved.

Likewise, the

role of the immune response to viral nonstructural proteins,
e.g. pX, and the cell mediated immune responses to both the
structural and non-structural viral proteins, must also be
examined.

Chapter IV
Cloning and Expression of Bovine Leukemia Virus gag,
env and tax Proteins using Eucaryotic Expression Vectors.
Introduction

BLV is a type C exogenous retrovirus that is the
etiologic agent of enzootic bovine leukosis (Deschamps et
al., 1981).

It is similar in structure, function and

pathological signs to the human T-lymphotropic viruses
(HTLV-I and HTLV-II)

(Burny et al., 1987b; Rice et al.,

1987b; Sagata et al., 1985b).

Cattle infected with BLV can

develop three different clinical symptoms.

An aleukemic

stage in which the infected animal shows no apparent signs
of disease, a persistent lymphocytotic stage in which the
animal has a persistently elevated lymphocyte count but is
otherwise "clinically normal", and a terminal
lymphosarcomatous stage in which lymphoid tumors are
detectable (Marshak et al., 1967; Abt et al., 1969; Burny et
al., 1987b).
Many serologic surveys have been conducted to evaluate
antibody responses to various viral proteins in an attempt
to elucidate the possible mechanism of disease progression
(Ferrer et al., 1974; Miller and Van der Maaten 1975; Bex et
al., 1979; Deshayes et al., 1980; Mammerickx et al., 1980;
Portetelle et al., 1981; Willems et al., 1987, 1988; Heeny
et al., 1988).

Antibody to BLV develops within 2-8 weeks

post infection, and antibody to gp50 and p24 is present in
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all BLV infected cattle, but no direct correlation of these
responses with disease progression has yet been made.
Likewise, these studies have demonstrated the presence of
antibodies against the non-structural proteins, p38 and pl8
of BLV in LS cattle but not in "clinically normal" cattle
(Sagata et al., 1985a; Yoshinaka and Oroszlan, 1985; Willems
et al., 1987, 1988; Burny et al., 1987a).

These proteins

are involved in trans-activation of the viral LTR and are
hypothesized to be involved in oncogenicity of the virus
(Derse 1987, 1988; Burny et al., 1987b; Itohara et al.,
1988).

They are produced in small quantities in the BLV

infected cell and have a half life of less than 6 hours
(Sagata et al., 1985a).

The presence of an increased

humoral immune response in these cattle may simply be due to
increased antigen exposure as the number of lymphocytes
containing the integrated provirus increases greatly during
the LS stage.
The significance of these humoral immune responses has
yet to be determined and their role in the prevention of
disease progression is unclear.

The protective response may

well involve cell mediated immunity.

MHC restricted, virus

specific cytotoxic T-lymphocytes (CTL) are known to play a
primary role in limiting viral replication and dissemination
(Zinkernagel and Doherty, 1976).

Differential killing by

BLV antigen specific CTL's may be the major controlling
factor in BLV disease progression.

In order to develop
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reagents to further evaluate the role of the humoral and
cell mediated immune responses to BLV proteins, we have
cloned the gag, env and px genes of BLV into a eucaryotic
expression vector.
Materials and Methods.

Antigen for use in the ELISA and Western assays was
prepared from pelleted supernate of BLV infected or
uninfected cells (Van der Maaten and Miller 1975a; Freshney,
1983; Chapter 3).

BLV purified on sucrose gradients (a gift

from Dr. Mark Newman, Louisiana State University), was used
in the production of monoclonal antibodies.
Monoclonal antibodies to BLV were derived from
hybridomas by the fusion of SP2/0 cells with the spleen
cells of BALB/c mice immunized with purified BLV using
standard methods (Oi and Herzenberg, 1980).

Initial

hybridoma screening was conducted using an ELISA assay
followed by indirect immunofluorescence on FLK-BLV cells and
Western blots to determine reactivity against specific viral
proteins.

Monoclonals were also isotyped.

Isotyping was performed using a kit obtained from ICN
immunobiologicals (Lisle, IL).

Briefly, 75 ul of monoclonal

supernates and lOul of each of six anti-sera are pipetted
onto a precut immunodiffusion plate and allowed to incubate
in a humidified chamber at room temperature for 24-48 hours.
Immunoprecipitation lines relevant to the immunoglobulin
specificity form around the appropriate well.

A positive
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serum control is supplied with each kit.
The ELISA was performed after overnight adsorbtion of
BLV antigen (100ng/50ul/well in .06M sodium bicarbonate
buffer pH9.6) or just bicarbonate buffer alone as a negative
antigen control to 96 well immulon microtest plates.

Plates

were blocked for 1 hr with 10% goat serum after which supernates diluted 1:2 were added to the plate and allowed to in
cubate at room temperature for 1 hr.

After washing 5x with

PBS, binding of murine monoclonal antibodies was detected
using biotinylated goat anti-mouse IgG (Sigma, St. Louis,
MO).

Avidin-biotin, horseradish-peroxidase (ABC Vectastain

Kit, Vector Laboratories, Burlingame, CA.) was added after a
second 5x wash step.

The enzyme reaction was developed by

the addition of 100 ul/well of the substrate solution [0.05M
citrate buffer, pH4.0 + l.Omg/ml Ortho-phenylenediamine
dihydrochloride (Sigma, St. Louis, MO.) + 0.5ul/ml of 30%
H202].

The reaction was stopped by the addition of 50ul/-

well of 2.5M sulfuric acid and absorbance at 495nm recorded
after reading plates on an automatic ELISA reader (Dynatech
Laboratories, Alexandria, VA.).

Negative antibody control

wells without monoclonal supernates (conjugate control),
without supernates or peroxidase conjugated second antibody
(antigen control) and negative mouse sera were included on
each plate.

Positive controls consisted of sera from BLV

inoculated mice at a 1:200 dilution.
Sodium dodecyl sulfate-polyacrylamide gel

electrophoresis (SDS-PAGE), Western transfer and
immunodetection of viral proteins by the monoclonal
antibodies were done using both purified and semi-purified
BLV as antigen.

Proteins (150ug purified or 700ug semi

purified BLV) were separated on 10% gels after dilution and
boiling at 100° for 5 min in sample buffer (0.05M Tris-HCL,
pH 6.8 + 10% glycerol + 2% SDS + 0.1% 2-mercaptoethanol)
essentially as described by Laemmli (1970). Samples were run
at 4 watts per gel for approximately 4 h.

For immuno

detection, proteins were eluted from polyacrylamide gels and
transferred to nitrocellulose paper in glycine transfer
buffer (20 mM Tris-base pH 8.3, 150 mM glycine and 20%
methanol) with a Trans-Blot apparatus (Bio Rad Laboratories,
Richmond, CA) at 75 volts for 2 h (Burnette et al., 1981).
Nitrocellulose paper was dried in a vacuum oven overnight,
cut into strips, and washed in TBS (150 mM NaCl, lOmM TrisHCL pH 7.4) for 5 minutes on a rocking platform.

Strips

were blocked for 30 min in 1% gelatin with 0.05% Tween-20 at
room temperature.

Supernates from monoclonal antibody

producing cell lines were diluted 1:2 using blocking buffer
and incubated with the strips for 1 1/2 h.

After washing 3X

(TBS plus 0.05% Tween-20), strips were incubated for 1 1/2 h
in peroxidase conjugated goat anti-mouse IgG (H&L) (Sigma
1:1000 in TBS) and washed again.

This was followed by the

addition of substrate [0.5mg/ml 4-chloro-l-naphthol (Sigma,
St. Louis, MO.) + 5ml methanol + 25ml 0.05M Tris pH 6.8 +
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12ul 30% H202].

After 30 min, the reaction was stopped by

rinsing the strips with distilled water.

BLV negative (non

immunized) and BLV positive (immunized) mouse sera were
included as controls.
Indirect Immunofluorescence assays were conducted on
cells after culture for 24-48 hours and fixing in 70% MEOH
for 10 min.

Fixed cells were blocked for 30 min with 10%

goat serum in PBS at 37"C in a humidified chamber, followed
by incubation for 30-60 min with monoclonal supernates
diluted 1:2 in blocking buffer.

After three five minute

washes with PBS and a distilled water rinse, slides were
allowed to dry.

Bound antibody was detected by incubation

with fluorescein conjugated goat anti-mouse IgG (H&L Sigma, ST. Louis, MO) diluted 1:100, for 30 min, followed by
washing and counterstaining with .05% Evans Blue.

Slides

were washed, dried and mounted using glycerol mounting
medium and examined under a Zeiss scope equipped with a
halogen source and epifluorescent illuminator.
Plasmids pENV-BL, pMB-SV and pBLV913,

(obtained from D.

Derse, NIH, Frederick, MD) contained the genes encoding the
env, p38 or entire genome of BLV respectively.

The genes

encoding gag, env and p38 were removed from these plasmids
and cloned into SV-40 based eucaryotic expression vectors
and transiently expressed in COS-1 cells constitutively ex
pressing the SV-40 large T antigen (Gluzman, 1981).
Conventional recombinant DNA techniques (Maniatis et al.,
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1982) were used to transform, purify, isolate and subclone
specific DNA fragments.

Plasmid pUC-19 and Escherichia coli

DH5a, were obtained from D.J. Messing through Bethesda
Research laboratories.

Plasmid pUC-19-Bgl is a pUC-19

derivative containing a modification in the polylinker site
to include a unique Bglll site immediately adjacent to the
Sail site.
The gag gene was cloned into transient expression
vector, P91023-B (R.J. Kaufman, Genetics Institute, Boston,
Ma) containing the adenovirus major late promoter,
tripartite leader sequence, VAI and VAII genes, DHFR gene
and the SV-40 origin of replication and polyadenylation site
(Sambrook and Gething 1988).

The gag gene was removed from

pBLV913, inserted into pUC-19-Bgl, checked for orientation,
excised and ligated into P91023-B as follows. Insertion of
the Sstl/BamHI fragment of pBLV913, containing the gag gene,
into pUC-19-Bgl at the unique BamHI site required a double
ligation procedure.

First, the BamHI end of the gag frag

ment was ligated to one of the complementary BamHI ends of
pUC-19-Bgl which had been previously treated with calf
intestinal alkaline phosphatase (CIAP).

The remaining un

ligated ends, BamHI (vector) and SstI (gag fragment) were
joined after first blunting with the Klenow fragment of DNA
polymerase I, to form pUC-19-Bgl-gag.

After transformation,

orientation was established by double digestion with
BamHI/EcoRI.

The gag fragment was removed from pUC-19-Bgl-
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gag by cutting with Bglll/EcoRI, and inserted in the correct
orientation into the complementary cut sites of p91023-B
(Figure 32).

The BLV ENV gene was cloned by removing it

from pENV-BL using EcoRI, and inserting it into the unique
EcoRI site of P91023-B that had been previously treated with
CIAP (Figure 33).
The p38 protein was cloned into transient expression
vector, CDM8 (Brian Seed, Mass General Hospital, Harvard,
Boston, Mass.).

This vector contains both the polyoma and

SV-4 0 origins of replication, under the control of the CMV
promoter.

In this procedure, the entire plasmid pMB-SV,

containing the p38 gene was cloned into the CDM8 vector.
Both plasmids were cut with Hindlll, pMB-SV was treated with
CIAP and the two plasmids ligated, to form CDM8-pUC-p38
(Figure 34).

Clones were examined for correct orientation

by digestion with BamHI.
For transient expression of BLV proteins, gp51, p24 and
p38, COS-1 cells were transfected with plasmid DNA using a
procedure based on the calcium phosphate method of Graham
and Van der Eb (1973).

COS-1 cells (supplied by W. Rutter,

University of California-San Francisco) were grown as mono
layers in DMEM with 10% FCS, NaHC03 and antibiotics, to 5070% confluency in 25 cm2 tissue culture flasks.

Purified

plasmid DNA (5-7ug) was mixed with 2.5M CaCl2 and 2xBBS [50
mM BES, (Sigma), 280 mM NaCl, 1.5 mM Na2HP04, pH 6.95] and
allowed to incubate at room temperature for 15-30 min.
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Cloning of BLV-ENV into p91023
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Medium was removed from the cells and 2ml of DEAE dextran
(Sigma, St. Louis, MO) at 500ug/ml in Tris-buffered saline
(TBS, 0.9% NaCl, 0.1M Tris-HCL, pH 7.4) was added for 2-3
min at room temperature.

After removing the DEAE by washing

2x with lOmls of TBS, the DNA mixture was brought up to 5
mis with DMEM and added to the flasks.

The cells were

incubated for 4-5 h at 37° in 5% C02, during this time, a
fine precipitate formed over the cells.

The medium and

precipitate were removed and cells subjected to glycerol
shock for one min (2ml of 15% glycerol in TBS).

Immediately

thereafter, 2ml of DMEM containing ImM sodium butyrate (Nbutyric acid, Sigma, St. Louis, MO) were added and the cells
incubated for 24 h at 37° in 5% C02.

After 24 h, the cells

were given fresh medium without butyrate and reincubated as
above for an additional 48 h.

For immunofluorescence

assays, cells were trypsinized at 24 h post-transfection,
reseeded into 24 well plates containing glass coverslips,
and reincubated for an additional 48 h.
CAT assay was performed using the single scintillation
vial method of Neumann et al. (1987) as amended by Dupont
(1989).

Cell lysates were prepared 48 h post infection

following the procedure of Fordis and Howard (1987).
Plasmids pSV0cat and

pBLH2cat were supplied by D. Derse

(NIH, Frederick, MD) and pSV2cat was supplied by L. Schultz
(LSU, Baton Rouge, LA) .

Plasmid pSV2cat was used as a

positive control, pSVQcat as a negative control, and pBLH2-
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cat contained the BLV LTR linked to the CAT gene.
Results and Discussion
Four monoclonal antibodies were identified which
reacted with purified BLV (Table 9) and against partially
purified BLV after 10X concentration (Table 10).

Reactivity

of these four monoclonals on western blots is demonstrated
in Figure 35.

Monoclonal 1.5G1-A11 and 1.5G1-D11 both

reacted with gp50 and 1.5A6-D12 and 1.2A7-A8 recognized p24.
All antibodies were of the IgG1 subclass.
Monoclonals A8 and D12 seemed to recognize two dif
ferent sites on p24 as evidenced by different binding pat
terns on Western blots (Figures 35 and 36).
recognized extra bands not detected using A8.

Antibody D12
The bands

present between 50kd and 24kd (Figure 36) may be cleavage
products of pr70gag.

Products of pr70gag identified by

anti-p24 antibodies include pr42 gag, pr40gag and pr35gag
(Mamoun et al., 1983a, 1983b) and pr45gag (Ghysdael et al.,
1979).

Gupta et al. (1980), using gel filtration chromatog

raphy of disrupted whole virus, demonstrated the presence of
a 65kd protein which was the precursor of p24, pl5 and pl2.
The presence of two bands of 28 and 26kd in addition to p24
results when virus is stored at -20°c for long periods of
time (Walker et al., 1987).

Based on the reactivity of

monoclonal antibody D12, we conclude that these proteins
contain p24.

Perhaps the precursor proteins are improperly

cleaved following long term cold storage resulting in
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Table 9.

Screening of Monoclonal Antibodies on
Gradient Purified BLV

Monoclonal

1:10

1.5A6D12
1.2A7A8
1.5G1D11
1.5G11A11

1.321
.08
.31
.09

Supernate Dilution
1:20
1 :40
1.10
.06
.27
.05

.93
.05
.21
.03

1:80
.69
.04
.16
.02

1Absorbance values obtained at 495nxn. ELISA was run as
described in text using gradient purified BLV as antigen.
Dilutions of monoclonal supernates were made in 10% goat
serum. Reactivity of monoclonals to negative control wells
(bicarbonate buffer only) was less than .01 for all samples.
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Table 10.

Reactivity of lOx Concentrated Monoclonals
on Pelleted BLV

Monoclonal

1:10

1.5A6D12
1.2A7A8
1.5G1D11
1.5G1A11

l.ll1
1.18
.92
.26

Supernate Dilution
1:20
1 :40
1.02
.98
.78
.18

.912
.92
.75
.12

'Absorbance values obtained at 495nm.
2Due to the increased reactivity of 1.5A6D12 over the other
monoclonals, all wells containing 1.5A6D12 were diluted 1:3
before read. The reported absorbance value is therefore an
indication of approximately one third of the actual
reactivity of D12 in this assay. ELISA was run as described
in text using pelletted BLV as antigen. Dilutions of
monoclonal supernates were made in 10% goat serum.
Reactivity of monoclonals to negative control wells
(bicarbonate buffer only) was less than .01 for all samples.

Monoclonal Antibodies Produced Against
Bovine Leukemia Virus Proteins

Figure 35. Bovine Leukemia Virus proteins separated
by SDS-PAGE and electrophoretically transferred to
nitro-cellulose. Western blot reactions of
monoclonal antibodies produced against BLV gp51 and
p24. Anti-gp51 monoclonals are shown in lanes 1 and
2, 1.5G1-A11 and 1.5G1-D11. Anti-p24 monoclonals are
shown in lanes 3 and 4, 1.5A6-D12 and 1.2A7-A8. Lane
5 shows reactivity against both proteins after mixing
Dll and A 8. This mix is referred to as A8+.
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Differences in Binding of Monoclonals Against p24
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Figure 36. Bovine Leukemia Virus proteins separated
by PAGE in a native system and electrophoretically
transferred to nitrocellulose. Western blot
reactions of monoclonals A8+ (anti-p24 and anti gp50), D12 (anti-p24) and Dll (anti-gp50). D12 demon
strates a different pattern of reactivity than does
A8 (A8 is anti-p24 portion of A8+) .
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production of these higher molecular weight proteins.

The

additional band at 17kd detected by antibody D12 may be from
breakdown of p24 itself, or perhaps another fragment of the
improperly cleaved gag precursor proteins that may result in
the previously discussed 26 and 28 kd protein bands.
The specificity of the anti-BLV monoclonal antibodies
for BLV proteins expressed in the cell in the native
configuration was demonstrated using FLK or FLK-BLV cells as
a source of negative and positive antigen respectively.

The

expression of cloned BLV structural proteins was also
confirmed using an indirect immunofluorescence assay.

The

reactivity of the monoclonals with the transfected cell
lines demonstrated the expression of antigenically correct
epitopes of BLV proteins.

Figure 37 shows the reactivity of

D-12 with P9-gag and Figure 38 shows D-ll with P9-env.
Neither monoclonal D-ll or D-12 reacted with cells
transfected with P9-gag or P9-env respectively.

This

procedure validated both the specificity of our monoclonals
against particular BLV proteins, and the production of
conformationally correct BLV structural proteins.
Due to a lack of monoclonal or polyclonal antibodies
directed against p38, we used the capability of p38 to
transactivate the BLV LTR in the chloramphenicol acetyltransferase (CAT) assay to demonstrate expression of
functional p38 protein.

Expression of CAT from pBLH2cat is

greatly increased when co-transfected with plasmid CDM8-pUC-

Indirect Immunofluoresence of p24 in
Transfected COS-1 Cells

Figure 37. COS-1 cells transfected with p9-GAG. Gag
protein p24 detected using D-12 (anti-p24) and indirect
immunofluoresence.

Indirect Immunofluoresence of gp50 in
Transfected COS-1 Cells

Figure 38. COS-1 cells transfected with p9-ENV. ENV
protein gp50 detected using D-ll (anti-gp50) and indirect
immunoflouresence.
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p38 containing the BLV trans-acting protein.

Increased

incorporation of 14C butyl-CoA by chloramphenicol is shown
in Figure 39.

Plasmids pSV0cat and pBLH2cat had essentially

no reactivity while pSV2cat and pBLH2cat + CDM8-pUC-p38
showed a linear increase with time.

This demonstrates the

production of functional p38 via trans-activation of the BLV
LTR found in plasmid pBLH2cat.
Although many studies have examined the humoral
immune responses to BLV structural proteins, little
correlation has been found between antibody titers and
disease progression.

Other areas must be examined to asses

their importance in the pathogenesis of BLV disease
induction.

Of particular interest is the CMI response to

each BLV protein as well as the humoral response to the
ubiquitous pX proteins.

This study will be simplified by

the use of clones of the various BLV proteins.
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Detection of Expression of BLV "Trans" acting Protein
using the CAT Assay and Chloraropenicol Butylation
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UC Butylation of Chloramphenicol by CAT.

COS-1 cells were transfected and prepared, and CAT
assay was ran as described.
1 = pSV0cat contains the CAT gene with no promoter.
2 = pBLHjCat contains the CAT gene under the BLV
promoter.
3 = pBLH2cat + pCDM8-p38 (double transfection)
Production of functinal p38 "trans" activates the
BLV promoter and increases CAT production.
4 = pSV2cat contains the cat gene under the SV40
promoter and acts as a positive control.
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Summary and Conclusions
To use in the various assays to detect BLV, monoclonal
antibodies against BLV envelope gp50 and gag p24 were produced
to confirm reactivity to specific proteins for the various
assays.

To confirm reactivity of monoclonals and produce

large amounts of selected proteins for later studies of BLV,
the genes for env, gag, and pX were cloned into eucaryotic
expression
plasmids,

vectors.

After

transfection

of

appropriate

correct expression of cloned genes was confirmed

using monoclonals and indirect immunofluorescence for gp50 and
p24 and CAT assay for px.
After experimental infection with BLV, whole blood and
serum samples were obtained from 12 holstein heifers for 103
weeks and used to correlate clinical signs (visual observation
and white blood cell counts) with changes in humoral immune
response

(Agar gel

immunodiffusion using envelope gp50

as

primary antigen, and ELISA and Western immunoblots using whole
BLV as antigen).

Total lymphocyte counts indicated 6 cattle

reached the PL stage during the 103 weeks post infection (PI) .
Cows progressed through three transient disease stages in the
first

3

months

PI:

transient

enlargement and lymphocytosis.

eosinophilia,

lymph

node

Of the 6 cattle demonstrating

early transient lymph node enlargement, 5/6 were AL.

Changes

in the humoral immune response to BLV were best detected using
Western immunoassays.

AL cattle were more likely to have an

increased antibody response to the gag protein p24 early PI
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as compared to PL cattle.

PL animals usually reached their

highest p24 antibody responses after conversion to the PL
stage.

Antibody response to env gp50 increased as a function

of time PI regardless of disease stage.

PL cattle tended to

recognize a greater number of the lesser gag proteins, pl5,
pl2 and plO in the first year PI than AL cattle.

All cattle

decreased markedly in their reactivity to any of these lesser
proteins after 51 weeks PI.
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Table 8.

Changes in Eosinophil Counts Early Post Infection.
Cow Number
123

132

144

149

0.3
0.7
1.0
0.7
3.6
1.3
2.4
0.5
1.8
2.4
0.9
1.4
2.5
1.4
1.3
0.9

0.3
0.4
0.3
1.1
0.8
0.7
0.9
1.9
1.6
1.1
0.5
0.7
0.3
0.5
0.9
0.9

0.3
1.1
0.6
0.4
1.4
0.6
1.1
1.9
0.9
0.9
1.0
1.0
0.5
0.8
1.1
0.0

1.9
1.3
1.6
1.1
1.3
1.4
1.5
3.3
2.3
2.8
2.4
2.2
2 .3
1.4
2.1
1.6

1.7
1.2
1.6
1.3
1.1
1.9
3.8
2.6
2.5
2.6
2.0
2.5
2.8
2.4
0.9
0.9

1.1
0.5
0.6
0.9
0.5
1.7
0.2
2.7
2.0
2.6
0.9
1.1
1.3
1.7
1.3
0.6

0.9
0.2
0.8
0.6
0.7
0.9
1.1
3.7
0.4
1.2
0.5
1.4
2.1
0.6
0.7
0.1

1.5
0.8
0.2
0.5
1.4
0.4
1.1
1.5
1.4
2.7
1.8
1.4
2.8
2.1
1.2
1.5

1.0
1.4
0.0
0.6
0.9
0.8
0.4
1.6
0.9
2.2
2.9
3.1
1.8
2.3
1.8
1.2

1.5

1.1

2.6

1.7

H

1.9

1.5

•

•

CM

122

•

99

CM

93

H

86

U)

0
1
2
3
4
5
6
7
8
9
10
11
12
16
20
25

76

H

WK
PI

The nine cattle which showed increased eosinophil counts
during the first 20 weeks post infection are listed. Counts
above which the cow is considered to have eosinophilia
(normal eosinophil count + 2.5 x SD) are listed in the last
row of each column. Counts which were increased are shown
in bold type for each animal.
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Figure 9. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 10. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples
and once every 2 months for
18 months (9 samples).
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Figure 11. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples
once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 12. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0) . Subsequent samples were
obtained once a week for 3 months (12* samples), once a month
for three months (3 samples
and once every 2 months for
18 months (9 samples).
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Figure 13. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 14. Total White Blood Cell and lymphocyte counts for the 103
week experimental period. Twenty five samples were analyzed. Just
prior to experimental infection with BLV one sample was obtained (week
0). Subsequent samples were obtained once a week for 3 months (12
samples
once a month for three months (3 samples
and once every 2
months for 18 months (9 samples).
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Figure 15. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples
once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 16. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 17. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 18. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 19. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figure 20. Total White Blood Cell and lymphocyte counts for
the 103 week experimental period. Twenty five samples were
analyzed. Just prior to experimental infection with BLV one
sample was obtained (week 0). Subsequent samples were
obtained once a week for 3 months (12 samples), once a month
for three months (3 samples), and once every 2 months for
18 months (9 samples).
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Figures 21-27. Western immunoassay was run as described in
text. Blots of antibody reactivity for cows 76, 122, 12 3,
131, 132, 144 and 149 are given. Antibody reactivity was
demonstrated against all the BLV structural proteins,
although not all cows possessed reactivity to all proteins.
The proteins shown by western include: gp50, gp30, p24,
pl5, pl2 and plO. Molecular weight markers are given on the
left and BLV proteins identified are labelled.

Western Immunoblot of Cow 76
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Figure 21

Western Immunoassay of Cow 122
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Figure 22

Western Immunoassay of Cow 123
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Figure 23

I

Western Immunoassay of Cow 131
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Figure 24

Western Immunoassay of Cow 132
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Western Immunoassay of Cow 144
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Figure 26

Western Immunoassay of Cow 149
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Figure 27
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